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LC  liquid crystal 
PABA  p-amino benzoic acid  
MGE  C17-monoglycerol ester 
GMO  glycerol monoolate   
TXA  tranexamic acid 
4-MS  4-methoxy- salicylic acid 
CC  catechin 
Cal  calcein 
SAXS  small-angle X-ray scattering 
L𝛼�  lamellar phase 
V2   cubic phase 
H2  hexagonal phase 
GI  gastrointestinal 
PHT  phytantriol 
ERT  C22-erythritol ester 
a  lattice parameter 
PBS  phosphate-buffered saline 
i.v.   intravenous 
p.o.   per oral 
i.p.   intraperitoneal 
AUC  the area under the plasma concentration-time curve 
Im3m              primitive type (body-centered lattice)  
Pn3m              diamond type (primitive lattice)  
Ia3d                gyroid type (body-centered lattice) 
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Abstract 
Liquid crystals (LCs) are semisolids made of lipids with crystalline structures 
combining the properties of both crystal and liquid states. First, the oral administration of LC 
formulations was evaluated. I aimed to develop oral formulations for delivering the drug to 
skin tissue with a high bioavailability using four different types of LC forming lipids 
(glyceryl monooleate (GMO), phytantriol (PHT), C17-monoglycerol ester (MGE) and C22-
erythritol ester (ERT)) containing a mal-absorptive model compound, p-amino benzoic 
acid (PABA), which is an active element in cosmeceuticals, dietary supplements and skin 
disorder medicines. The bioavailability and skin concentration of PABA were investigated 
after its oral administration in rats. The effect of the remaining amount of the LCs 
formulations in the stomach on the bioavailability of orally administered PABA was 
evaluated. The skin permeation and concentration of PABA were also investigated using in 
vitro permeation experiment. As a result, the bioavailability of PABA was significantly 
improved by administration of PABA-LC formulations compared with that of PABA 
solution alone, although the remaining effect in the stomach was greatly influenced by the 
type of LC-forming lipids. The in vitro skin permeation study showed that the PABA 
concentration in skin when applied from the dermis side was higher than when applied from 
the epidermis side. These findings suggested that oral administration advantageously 
supports skin drug delivering, and oral LC formulations could be a promising dosage form 
in cosmeceutical, dietary and clinical fields.  
Next, the usefulness of topical LC formulations with skin permeation enhancing 
ability was investigated. A rather new LC forming lipid, C17-monoglycerol ester (MGE) was 
evaluated and compared with glycerol monoolate (GMO), which is considered as the gold 
standard for forming LC formulations. I initially prepared LC formulations containing drugs 
with different physicochemical properties (tranexamic acid (TXA), 4-methoxy-salicylic acid 
(4-MS), catechin (CC) and calcein (Cal), and confirmed LC phase structures in the prepared 
formulations by a polarizing light microscope and a small-angle X-ray scattering (SAXS). 
Physicochemical properties of these formulations were also performed using a viscometer 
and a zetasizer. The release rate of the drugs from LC formulations was determined using a 
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dialysis membrane method. The skin penetration-enhancing ability of LC formulations was 
also investigated by in vitro skin permeation study. The obtained results showed that both 
MGE and GMO LC forming lipids exhibited the same behavior in terms of their 
birefringence indices, LC phase structures, particle sizes and zeta potentials. Both the LC 
formulations consisted of MGE and GMO were managed to improve the skin permeation for 
various physicochemical properties of drugs. However, MGE formulations showed lower 
viscosity, faster drug release rate and better skin penetration-enhancing ability than GMO 
formulations, which strongly suggesting that the low viscosity of LC forming lipid of MGE 
might influence drug diffusivity and drug permeability through skin. The present MGE-LC 
formulations can be utilized as a promising new topical formulation for therapeutic drugs and 
cosmetic ingredients. 
Finally, I aimed to develop strategies for designing and optimizing LC formulations 
to overcome the challenges of poor bioavailable drugs after oral administration and 
transdermal application by evaluating the physicochemical characterizations of the designed 
formulations and their ability for in vitro and in vivo absorption performance. Very limited 
studies have investigated on the effect of physicochemical properties of entrapped drugs, 
percentage of LC forming lipids and phase structure of LC formulations on the drug 
absorption from these formulations after oral or topical administration. In this study, various 
oral and topical LC formulations were designed based on the changes of LC forming lipid 
contents in the formulations entrapped with different physicochemical properties of drugs. 
The obtained results showed that the drug absorption after oral and topical administration of 
LC formulations were dramatically affected by the percentage of LC forming lipid and 
physicochemical properties of drugs. An understanding of the effect of such factors could 
enable us to prepare LC formulations with improved oral absorption and skin permeation of 
drugs. 
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General introduction 
Liquid crystal (LC) forming lipids represent an important class of biocompatible 
amphiphiles and their application extends to several fields, such as cosmeceutical, dietary 
and pharmaceutical technologies. During the last few decades, increasing attention has been 
paid to the LC formulations including cubosomes and hexosomes because of their remarkable 
structural complexity and usefulness in diverse application and the LC phases formed by LC 
forming lipids have been applied to accommodate biologically active molecules such as 
vitamins, enzymes and other proteins. This ability opens new possibilities for pharmaceutical 
applications. The advantages of LC formulations as a drug delivery system are their high 
biocompatibility and self-assembly ability of their structures. This study mainly focuses to 
overcome the challenges of poorly bioavailable drugs through oral administration and 
transdermal application using a chemical approach representing by LC formulations. This 
study is divided in three chapters as follows: the first chapter was aimed to develop oral 
formulations for delivering the drug to skin tissue with a high bioavailability using four 
different types of LC forming lipid (glyceryl monooleate (GMO), phytantriol (PHT), C17-
monoglycerol ester (MGE) and C22-erythritol ester (ERT)) containing a mal-absorptive 
model compound, p-amino benzoic acid (PABA), which is an active element in 
cosmeceuticals, dietary supplements and skin disorder medicines. The bioavailability and 
skin concentration of PABA were investigated after oral administration in rats. The second 
chapter of this study was aimed to develop topical LC formulations with skin-permeation 
enhancing ability. Two different types of LC forming lipids were used: GMO and MGE. 
GMO is one of the most widely studied LC forming lipids used in the formation of various 
LC drug formulations; whereas, no studies have utilized the skin-permeation enhancing 
ability of MGE as a chemical enhancing approach. Both the MGE- and GMO-LC 
formulations managed to improve the skin-permeation of various drugs with a range of 
physicochemical properties. However, MGE formulations showed lower viscosity, faster 
drug release rate and better skin-penetration enhancing ability than GMO formulations, 
strongly suggesting that the low viscosity of MGE-LC-forming lipids might influence drug 
diffusivity and permeability through the skin. The present MGE-LC formulation might be 
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utilized as a promising new topical formulation for therapeutic drugs and cosmetic 
ingredients. The third chapter of this study was aimed to develop strategies for designing 
and optimizing oral and topical LC formulations by evaluating the effect of several factors 
such as physicochemical properties of the entrapped drugs and concentration of LC-forming 
lipids and LC phase structure on the performance of these formulations. Results showed that 
the concentration of LC-forming lipid and the physicochemical properties of entrapped drugs 
are key issues for good performance of the LC formulations in various pharmaceutical 
applications. Understanding the effect of these factors on the LC formulation performance 
could enable researchers to develop LC formulation approaches that intended to improve the 
oral absorption and skin-permeation of drugs. 
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Chapter 1 
Usefulness of liquid crystal-oral formulations to enhance the bioavailability and skin 
tissue delivering of p-amino benzoic acid as a model compound 
 
1.1. Introduction 
Skin is utilized as an application site for many topical and transdermal drug delivery 
systems. A variety of topical drug formulations and transdermal drug delivery systems have 
been developed to treat local indications and systemic diseases. However, topical 
formulations are not always suitable for treating broad areas of skin, especially in the case of 
UV protection agents, dietary and cosmetic skin supplements and several skin disorder 
medicines. Topical application for a broad area skin is often associated with certain 
drawbacks such as staining of clothes, sweating, pigmentation and skin irritation. Moreover, 
only a limited number of drugs are amenable to administration by topical application and it 
is not a practical route to cover large areas of skin on a daily basis [1, 2]. These limitations 
are associated with a number of drugs not only as medicines for skin disorders but also in 
dietary and cosmetic skin supplements.  
In the present study, I aimed to improve the oral bioavailability and skin tissue 
delivering of p-amino benzoic acid (PABA) as a model compound with a formulation 
approach by utilizing liquid crystals (LC). LCs are semisolids made of lipids with crystalline 
structures combining the properties of both crystal and liquid states. Molecules in crystal are 
highly ordered, while those in liquid are free to diffuse in a random way. Thus, molecules in 
LC phases diffuse like the molecules in liquid but contain some degree of order [3-6]. A 
generally used term is the mesophase for LC, indicating such a unique structure is between 
those of true liquid and solid crystals [7]. In general, LCs can be classified into two categories, 
i.e., thermotropic and lyotropic. Thermotropic LCs are formed by a change in temperature, 
whereas lyotropic phases are obtained when mixed with some solvent. Lyotropic LCs usually 
consist of amphiphilic substances like surfactants and solvents. Amphiphilic substances 
become micelle at a low concentration, having cluster of molecules with their polar groups 
oriented in the water. This is a liquid isotropic phase, where isotropic means identical 
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properties of the structure in all directions. More ordered structures such as hexagonal, 
lamellar and cubic phases are formed at higher concentrations. These structures are formed, 
due to insufficient water to fill up spaces between the spherical or elongated micelles [8, 9]. 
Depending on the solvent concentration and the polarity of solvated mesogen, these systems 
can undergo phase transitions and structure modifications. Thus, their consistencies and 
rheological properties can be systematically changed as required [7, 10]. Lyotropic LCs 
formed with aqueous surfactants can absorb water from the environment, inducing 
spontaneous phase-transition and forming lamellar phase (L𝛼�), cubic phase (V2) and 
hexagonal phase (H2) [11, 12]. Among them, cubic phase and hexagonal phase have received 
much attention due to their highly ordered internal structures, and can be used as a slow 
release matrix for active pharmaceutical ingredients with various molecular sizes and 
polarities [13, 14]. Cubic and hexagonal LCs are often spontaneously formed by addition of 
certain amphiphilic lipids in an aqueous environment [15]. When these LCs are dispersed 
into nanoparticles by addition of excess water with stabilizers such as Pluronic copolymers 
and Myrj series [16], they form stable colloidal dispersions which are termed cubosomes and 
hexosomes, respectively [17-20]. 
PABA also known as vitamin Bx was selected as a model compound, which is 
widely found in foods as a cofactor of the vitamin B complex [21]. PABA is often used as an 
ingredient in sunscreen owing to its high absorbance in the UVB region, and it is protective 
against skin cancers. Protection against UV and free radical damage is related to the ability 
of PABA to scavenge reactive oxygen species [22]. It is also available as a health supplement 
(vitamin B10) because of its antioxidant activity [23]. The potassium salt of PABA is used as 
a prescription drug in the USA for the treatment of skin disorders such as scleroderma, 
dermatomyositis and Peyronie’s disease [24-26]. Based on these findings, PABA is 
considered as an active element in cosmeceuticals, dietary supplements and skin disorder 
medicines. However, PABA suffers from a narrow absorption window in the gastrointestinal 
(GI) tract [27].  
During the last few decades, increasing attention has been paid to LC formulations 
including cubosomes and hexosomes because of their remarkable structural complexity and 
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usefulness in diverse applications [28], but very few studies demonstrated their use in vivo 
or particularly for the investigation of their application to oral drug delivery and skin tissue 
delivering. The first chapter was undertaken with the intention of enhancing the oral delivery 
and skin tissue delivering of PABA using LC formulations and evaluating LCs as a drug 
delivery system. Oral LC formulations containing PABA were prepared using the following 
LC forming lipids: glyceryl monooleate (GMO), phytantriol (PHT), C17-monoglycerol ester 
(MGE) and C22-erythritol ester (ERT) (Fig. 1-1). 
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Fig. 1-1. Chemical structures of glyceryl monooleate (GMO), phytantriol (PHT), C17-
monoglycerol ester (MGE) and C22-erythritol ester (ERT). 
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The confirmation of LC phase structures in the presence of PABA was determined 
by small-angle X-ray scattering (SAXS). The physicochemical measurements of these 
formulations were performed using a viscometer and a Zetasizer. The in vitro release of 
PABA from LC formulations was determined using a dialysis release method. PABA solution 
or its dispersed LC formulations were administrated to rats, and the bioavailability, stomach 
remaining contents and skin concentration of PABA were determined. Furthermore, the skin 
permeation and concentration were investigated using in vitro skin permeation studies. 
 
1.2. Materials and methods 
1.2.1. Materials 
PABA was purchased from Kanto Chemical Co., Inc. (Tokyo, Japan). GMO with a 
normal purity of > 97% and MGE with a normal purity of > 99.56% were purchased from 
Farnex Co., Inc. (Yokohama, Japan). PHT with a normal purity of > 95% and ERT with a 
normal purity of > 97% were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, 
Japan). A surfactant, Pluronic® F127, was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Other reagents and solvents were of special grade or HPLC grade and used without 
further purification. 
1.2.2. Preparation of PABA-LC formulations 
Table 1-1 shows the composition of dispersed PABA-LC formulations prepared in 
this study. These formulations were designed based on a 1:1 ratio of the active ingredient 
(PABA) solution and LC forming lipids. The mixture was dispersed using an ultrasonic 
homogenizer (USP-50; Shimadzu Corp., Kyoto, Japan) in a pulsing mode (5-s pulse 
interrupted by 1-s pauses) for 15 min. GMO was melted at 50C before use, but ERT was 
hard to melt even at 100C. Other LC forming lipids were dispersed with PABA solution 
without preheating. The dispersion for PABA-GMO, -PHT and -MGE formulations 
produced uniform opaque creamy mixtures. These formulations were able to be orally 
administered to rats via an oral zonde needle, although a non-uniform mixture with gel-like 
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highly viscous aggregates was observed in case of the PABA-ERT formulation. No further 
work was carried out using PABA-ERT formulation owing to high melting point of ERT. 
 
Table 1-1 Composition of dispersed PABA-LC formulations 
 
Ingredients (%)  PABA-GMO    
20 mM 
PABA-PHT  
20 mM 
PABA-MGE 
20 mM 
PABA-ERT      
20 mM 
GMO 30 --- --- --- 
PHT --- 30 --- --- 
MGE --- --- 30 --- 
ERT --- --- --- 30 
PABA solution 30 30 30 30 
Purified water 
containing 5% 
Pluronic® F127  
 
40 
 
40 
 
40 
 
40 
Total % 100 100 100 100 
 
 
1.2.3. SAXS measurement 
SAXS measurement of dispersed PABA-GMO, -PHT and -MGE formulations was 
performed using a Nano-Viewer (Rigaku, Tokyo, Japan) with a Pilatus 100K/RL 2D detector. 
The X-ray source was Cu Kα radiation with a wavelength of 1.54 Å and operating at 45 kV 
and 110 mA. The sample-to-detector distance was set at 375 mm. Each sample was placed 
into a vacuum-resistant glass capillary cell and exposed at 25C for 10 min (Fig. 1-2). The 
obtained SAXS pattern was plotted against the scattering vector length,    ,2/sin/4 q
where   is scattering angle. The lattice parameter (a) was obtained from the gradient of the 
plot of q as a function of 222 lkh  using the following equation: 
  222/2 lkhaq  , where h, k, and l are the Miller indices. The scattering intensity 
was normalized by decayed direct beam intensity. 
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Fig. 1-2. An illustration explains the principle of SAXS. 
 
1.2.4. Measurement of particle size and viscosity 
The particle size of LC formulations with or without PABA was measured using a 
dynamic light scattering Nano-ZS ZEN3600 Zetasizer (Malvern Instruments Ltd., 
Worcestershire, UK) at 25C and 37C. Samples were diluted 10000-fold in water and 
shaken using a vortex mixer prior to measurement. In addition, the viscosity of LC forming 
lipids and PABA-LC formulations was measured at 25°C and 37°C using a viscometer (Toki 
Sangyo Co., Ltd., Tokyo, Japan) that allowed a sensitive determination of viscosity within a 
range of 0.3-10000 mPa·s with an accuracy of 1% relative error. 
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1.2.5. Analytical procedures 
The in vivo or in vitro study sample (50 µL) was mixed with the same volume of 
acetonitrile (to precipitate plasma proteins) containing methyl paraben (10 µg/mL) as an 
internal standard and centrifuged (5 min, 4C). The obtained supernatant (20 µL) was 
injected into an HPLC system. The HPLC system (Shimadzu, Kyoto, Japan) consisted of a 
system controller (CBM-20A), pump (LC-20AD), auto-sampler (SIL-20AC), column oven 
(CTO-20A), a UV detector (SPD-M20A), and analysis software (LC Solution). The column 
was an Inertsil® ODS-3 (5 µm, 4.6 × 250 mm) (Nihon Waters K.K.; Tokyo, Japan), which 
was maintained at 40C. The mobile phase was acetonitrile : 0.1% phosphoric acid = 8 : 52 
(0-4 min), 35 : 65 (4-14 min) and 8 : 92 (14-20 min). The flow rate was adjusted to 
1.0 mL/min. PABA was detected at UV 280 nm. In the case of skin samples, the skin piece 
(0.1 g) was minced with scissors and homogenized (5 min, 4C) with water (0.9 mL) using 
a homogenizer (Polytron PT-MR 3000; Kinematica Inc., Littau, Switzerland). The 
homogenate was mixed with acetonitrile : water = 1:1 (0.5 mL) and agitated for 15 min. After 
centrifugation (5 min, 4C), the supernatant (50 µL) was mixed with the same volume of 
acetonitrile containing methyl paraben (10 µg/mL) and centrifuged again (5 min, 4C). The 
obtained supernatant (20 µL) was injected into an HPLC system, and the measurement was 
obtained with the same conditions as mentioned above. 
1.2.6. In vitro dialysis release study 
The in vitro release study was performed using dialysis bags (Eidia Co., Ltd., Tokyo, 
Japan). Prior to use, the dialysis bags were soaked in distilled water for 1 h. Phosphate-
buffered saline (PBS) as a solvent with physiological pH (7.4) or 0.1 M HCl to simulate 
gastric conditions (300 mL each) was used as a receiver medium and continuously stirred at 
300 rpm in a beaker and warmed in a water bath at 37C. A dialysis bag was then loaded 
with 1.0 mL of 20 mM PABA or PABA-LC formulation and placed in the beaker. An aliquot 
(0.5 mL) was withdrawn from the receiver beaker and the same volume of pH 7.4 PBS or 0.1 
M HCl was added to the beaker to keep the volume constant. The concentration of released 
PABA was then determined using an HPLC in conditions as explained in Section 1.2.5. The 
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cumulative % PABA release was plotted against the square root of time (Higuchi model) 
[29]. 
1.2.7. Animals 
Male Wistar rats (200-250 g) were purchased from Sankyo Labo Service Co., Inc. 
(Hamamatsu, Japan). Male hairless rats were purchased either from Life Science Research 
Center, Josai University (Sakado, Saitama, Japan) or Ishikawa Experiment Animal 
Laboratories (Fukaya, Saitama, Japan). Animals were housed in temperature-controlled 
rooms (25 ± 2C) with a 12 h light-dark cycle (7:00-19:00 h). The rats were allowed free 
access to food (Oriental Yeast Co., Tokyo, Japan) and tap water. The animal care protocol 
was approved by the Animal Care and Use Committee of Josai University (Sakado, Saitama, 
Japan). 
1.2.8. Bioavailability and skin samples excising 
Intravenous (i.v.) and per oral (p.o.) administrations were performed in Wistar rats 
under anesthesia by intraperitoneal (i.p.) injection of three types of anesthesia (medetomidine, 
0.375 mg/kg; butorphanol, 2.5 mg/kg; and midazolam, 2 mg/kg) to determine the 
bioavailability of PABA. In case of i.v., PABA dissolved in physiological saline (PABA 
solution) was injected (10 µmol/kg) into the tail vein. Blood samples (0.2 mL) were collected 
from the jugular vein at predetermined intervals up to 3 h, and the same volume of saline was 
injected via the tail vein to prevent severe changes the in volume of distribution. For p.o 
administration, PABA solution or its dispersed LC-formulation (20 µmol/kg) was 
administered to rats, and blood (0.2 mL) was sampled from the jugular vein at intervals up 
to 8 h and the same volume of saline was injected via tail vein. Blood samples placed into 
heparinized tubes were immediately separated by centrifugation to obtain plasma (5 min, 
4C). Skin samples were taken from the abdomen area at 0.5 or 3 h after p.o. administration. 
Plasma and skin samples were stored at -30C until analysis. 
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1.2.9. Determination of PABA concentration remaining in the stomach 
Rats were sacrificed at 3 and 8 h after p.o. administration of PABA solution or its 
dispersed LC formulation, and the stomach was removed and the internal lining was scraped 
with a scalpel blade to collect the stomach contents. The contents were mixed with 
acetonitrile : ethanol = 2:1 to dissolve the lipid phase and agitated for 15 min. The supernatant 
(50 µL) after centrifugation (5 min, 4C) was mixed with the same volume of acetonitrile 
containing methyl paraben (10 µg/mL) and centrifuged (15,000 rpm, 5 min, 4C) [28]. The 
obtained supernatant was diluted 100-fold and injected (20 µL) into an HPLC system. The 
measurement was obtained as described in Section 1.2.5. 
1.2.10. In vitro skin permeation study 
Full-thickness hairless rat skin was excised from the abdomen under anesthesia by 
i.p. injection of three types of anesthesia (medetomidine, 0.375 mg/kg; butorphanol, 2.5 
mg/kg; and midazolam, 2 mg/kg). The excess fat was trimmed off and the skin samples were 
set in vertical-type diffusion cells (effective diffusion area: 1.77 cm2) with the epidermis side 
facing the donor compartment (epidermis to dermis) or facing the receiver compartment 
(dermis to epidermis). Skin permeation experiments were conducted after hydration for 60 
min with PBS pH 7.4 at 32°C. PABA solution (20 mM, 1.0 mL) and PBS (6.0 mL) were 
added to the donor and receiver compartments, respectively, in all permeation experiments. 
The receiver solution was agitated using a stirrer bar and a magnetic stirrer throughout the 
experiments. An aliquot (0.5 mL) was withdrawn from the receiver chamber and the same 
volume of PBS was added to keep the volume constant. PABA concentration in the receiver 
was determined using an HPLC as described in Section 1.2.5. The donor solution was 
removed and the skin sample was washed with PBS after the permeation experiment. The 
permeation area of the skin (1.77 cm2) was then cut and stored at -15C until analysis. The 
skin concentration was measured as described in Section 1.2.5. 
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1.2.11. Determination of AUC 
The area under the plasma concentration-time curve (AUC) was calculated using the 
linear trapezoidal rule. The absolute bioavailability was determined as AUCpo/AUCiv, using 
the mean AUC values for p.o. and i.v. doses. Statistical analysis was performed using 
unpaired Student’s t-test (ANOVA), and P values less than 0.05 were considered to be 
significant. 
 
1.3. Results 
1.3.1. SAXS evaluation of LC formulations 
The phase behavior of dispersed PABA-LC (PABA-GMO, -PHT and -MGE) 
formulations was evaluated by SAXS. Figure 1-3 shows the X-ray diffraction profiles and 
the lattice parameter (a) of the three PABA-LC formulations. Table 1-2 summarizes the peak 
position (q) and intensity of these formulations. These typical reflection patterns; for 
dispersed PABA-GMO formulation at nearly √2, √3, √4, √6, √8, √9 (a), PABA-PHT 
formulation at nearly √2, √3, √4, √6, √8, √9 (b) and PABA-MGE formulation at nearly √2, 
√3, √4, √6, √8, √9 (c), revealed the presence of inverse bicontinuous cubic (V2) Pn3m phase 
for the three formulations [30, 31]. 
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Fig. 1-3. SAXS profiles and lattice parameter (a) of PABA-GMO formulation (a), PABA-
PHT formulation (b) and PABA-C17-MGE formulation (c). 
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Table 1-2 Peak position (q) and intensity observed in Bragg reflection of PABA-LC 
formulations 
 
 
 
 
 
 
 
 
Formulation Peak position (q)  
(nm-1) 
Intensity 
 (cps)  
PABA-GMO 0.982 1412 
 1.203 545.8 
 1.388 219.8 
 1.623 192 
 1.979 169 
PABA-PHT 1.352 698 
1.659 470 
 1.915 169 
 2.376 126 
 2.772 64 
PABA-MGE 1.381 1088 
 1.694 609 
 1.95 189 
 2.406 136 
 2.755 69 
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1.3.2. Particle size and viscosity of LC formulations 
The particle sizes of LC formulations with or without PABA in Pluronic® F127 
solution were measured by a dynamic light scattering at 25°C and 37°C. Table 1-3 lists the 
obtained particle sizes. The particle size was nearly 200-400 nm for all formulations, 
suggesting that the presence of PABA and temperature changes did not affect the particle 
size of LC formulations. 
Table 1-3 Particle size (nm) of LCs 
 Dispersed with 
PABA at 25°C 
Dispersed with 
PABA at 37°C 
Without PABA 
at 25°C 
Without PABA 
at 37°C 
GMO 212 ± 15 254 ± 12 244 ± 21 239 ± 23 
PHT 332 ± 31 361 ± 34 319 ± 22 352 ± 38 
MGE 289 ± 25 320 ± 31 311 ± 27 306 ± 12 
Each value represents the mean ± S.E. of 3 experiments. 
 
Moreover, the viscosity of LC forming lipids and their PABA formulations was 
measured using a viscometer at 25°C and 37°C. Table 1-4 lists the obtained viscosity values. 
The viscosity grades of LC forming lipids and their PABA formulations were affected 
dramatically by changes in experimental temperature, except for the MGE-LC forming lipid 
and its PABA formulation, suggesting that MGE-LC forming lipid is more thermally stable 
compared with other LC forming lipids. 
Table 1-4 Rheological properties of LC forming lipids and LC formulations 
 At 25°C At 37°C 
GMO alone* > 10000 187 ± 23 
PHT alone* 8619 ± 34 2019 ± 103 
MGE alone* 560 ± 41 175 ± 27 
PABA-GMO formulation 6422 ± 133 2193 ± 213 
PABA-PHT formulation 7231 ± 183 4331 ± 198 
PABA-MGE formulation 1890 ± 201 1101 ± 112 
*: LC forming lipid only without water or any additive.  
Each viscosity (mPa.s) represents the mean ± S.E. of 3 experiments. 
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1.3.3. In vitro drug release from LC formulations     
 The in vitro release study was performed using dialysis bags. PBS as a solvent with 
physiological pH (7.4) or 0.1 M HCl for gastric conditions was used as the receiver medium. 
Figure 1-4 shows PABA release profiles from LC formulations into PBS pH 7.4 (a) and 0.1 
M HCl (b). The PABA release profile into 0.1 M HCl was similar to that when PBS was used 
as the receiver medium, indicating that changes in pH probably did not affect the release rate 
of PABA from its solution or its LC formulations. The PABA release profile from the LC 
formulations was a relatively slow and gradual till 60 min compared with that from PABA 
solution. The release profiles of PABA from its GMO and MGE formulations were similar 
each other. Higuchi’s square-root model analysis showed two phases of PABA release; a fast 
release phase (5-60 min), followed by a slow release phase (60-240 min) of PABA from the 
LC-matrix. The correlation coefficients of PABA-LC formulations were calculated in 
accordance with the release profiles obtained using square root Higuchi model as shown in 
Table 1-5. 
The amount of PABA released from GMO, PHT and MGE were 81 ± 3, 67 ± 2 and 
90 ± 4%, respectively, against the initial dosing. These results showed that the release profile 
of PABA from the PHT formulation was slower than that from other PABA-LC formulations 
and could be related to its high viscosity at 37°C, which could lead to reduced mobility of 
PABA in this formulation compared with other PABA-LC formulations. 
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Fig. 1-4. Percentage of p-amino benzoic acid (PABA) release profiles into phosphate-
buffered saline (PBS) pH 7.4 (a) and 0.1 M HCl (b). Symbols: (●), PABA solution; (), 
PABA-glyceryl monooleate (GMO) formulation; (), PABA-phytantriol (PHT) 
formulation; and (□) PABA-C17-monoglycerol ester (MGE) formulation. Each point 
represents the mean ± S.E. of three experiments. 
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Table 1-5 Correlation coefficients* of PABA-LC formulations  
 Fast release 
phase (pH 7.4) 
Slow release 
phase (pH 7.4) 
Fast release phase 
(0.1 M HCl) 
Slow release phase 
(0.1 M HCl) 
PABA-GMO 0.9965 0.9993 0.9965 0.9992 
PABA-PHT 0.9902 0.9974 0.9937 0.9904 
PABA-MGE 0.9936 0.9973 0.9881 0.9791 
 
*: The correlation coefficients were obtained by data from 5-60 and 60-240 min as a 
represent to the fast release phase and the slow release phase, respectively. 
 
1.3.4. Bioavailability of PABA after oral administration of LC formulations 
Figures 1-5 and 1-6 show the time course of the plasma concentration of PABA after 
i.v. and p.o. administration of its solution or LC formulations in male Wistar rats, respectively. 
Table 1-6 summarizes the calculated AUC0-6 h, Tmax, Cmax and bioavailability of PABA after 
administration of PABA solution or its dispersed LC formulations. The Cmax after oral 
administration of dispersed PABA-MGE or -GMO formulations was significantly higher 
than with PABA solution. The Tmax for administration of dispersed PABA-MGE formulation 
was faster compared with PABA solution and other PABA-LC formulations. In addition, the 
bioavailability of PABA was significantly improved by administration of dispersed PABA-
MGE or -GMO formulations compared with PABA solution. Although the PABA-PHT 
formulation resulted in a significant improvement in bioavailability, a relatively lower Cmax 
was obtained compared with the other formulations. No plasma concentration was observed 
6 h after administration except for the PHT formulation, for which a very low concentration 
of PABA (3 ± 1 nmol/mL) was observed at 8 h (not shown in Fig. 1-6).  
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Fig. 1-5.  Plasma profile after intravenous injection of PABA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-6. Plasma profiles of PABA after oral administration. Symbols: (●), PABA solution; 
(), PABA-GMO formulation; (), PABA-PHT formulation; and (□) PABA-MGE 
formulation. Each point represents the mean ± S.E. of three experiments. 
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Table 1-6. Bioavailability of PABA after oral administration of its solution or its dispersed 
LC formulation 
 AUC 0-6 h Tmax (min) Cmax (µM) Bioavailability 0-6 h (%) 
PABA solution 774 ± 77 33 ± 5 13 ± 2.3 19 ± 2 
GMO-PABA 3203 ± 107* 38 ± 5 27 ± 2.4* 78 ± 3* 
PHT-PABA 1467 ± 98* 30 ± 8 15 ± 0.89 62± 10* 
MGE-PABA 3887 ± 539* 26 ± 9 36 ± 3.7* 91 ± 13* 
Each value shows the mean ± S.E. of 3 experiments. 
*: P < 0.05 significantly different from PABA solution (Student’s t-test). 
 
1.3.5. Skin concentration of PABA 
Figure 1-7a and b show the skin concentration of PABA 30 min and 3 h, respectively, 
after oral administration of PABA solution or its dispersed LC formulation. A significant 
improvement in the skin concentration at 30 min was observed with the GMO and MGE LC 
formulations compared with PABA solution, but no improvement was observed using the 
PHT formulation. No detection of PABA in skin was observed 3 h after application of PABA 
solution. However, LC formulations sustained a low concentration of PABA in the skin even 
3 h after administration. These results suggested that GMO and MGE formulations were 
more efficient for enhancing the skin concentration of PABA than PABA solution and PHT 
formulation. 
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Fig. 1-7. Skin concentration of PABA: (a) 30 min after oral administration of PABA solution 
or its LC formulation; (b) 3 h after oral administration of PABA solution or its LC 
formulation. Each column represents the mean ± S.E. of three experiments. *: P < 0.05 
significantly different from PABA solution (Student’s t-test). 
 
1.3.6. Concentration of PABA remaining in the stomach 
In order to estimate the sustained release of PABA from LC formulations, the PABA 
concentration remaining in the stomach was determined 2 and 8 h after p.o. administration 
of its solution or LC formulation. LC dispersions were observed to accumulate in the pyloric 
region of the stomach, as shown in Fig. 1-8. Figure 1-9 shows nearly 40% of the total dose 
of PABA concentration from the PHT formulation remained in the stomach 2 h after 
administration, and nearly 20% remained from the GMO and MGE formulations (Fig. 1-9a). 
No PABA was detected 8 h after administration of PABA solution or GMO and PHT 
formulations, but nearly 12% of the total dose of PABA in the PHT formulation remained in 
the stomach 8 h after administration (Fig. 1-9b). The high percentage of PABA remaining in 
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the stomach for the PHT formulation must be consistent with its high viscosity, leading to a 
prolonged emulsification effect of the formulation in the stomach. 
 
 
 
 
 
 
 
 
 
 
Fig. 1-8. An illustrative photograph of the remaining dispersed PABA-LC formulation in the 
stomach of rats after oral administration. 
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Fig. 1-9. The percentage of PABA remaining in the stomach: (a) 2 h after oral administration 
of PABA solution or its dispersed LC formulation; (b) 8 h after oral administration of PABA 
solution or its dispersed LC formulation. Each column represents the mean ± S.E. of three 
experiments. 
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1.3.7. In vitro skin permeation study 
Figure 1-10 shows the time course of cumulative amount of PABA that permeated 
through the full-thickness skin of hairless rats. Almost no change was observed in the skin 
permeation profile of PABA after application to the epidermis side or the dermis side. 
However, PABA skin concentration was significantly higher when applied on the dermis side 
compared with the epidermis-side application, as shown in Fig. 1-11. This indicated that the 
partition of PABA to skin tissue from the dermis side was higher than that from the epidermis 
side; and this supported for usefulness of p.o. administration, especially for delivering of 
PABA to the skin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-10. In vitro skin permeation study: time course of the cumulative amount of PABA 
that permeated through full-thickness hairless rat skin. Symbols: (■), from the dermis to 
epidermis; and (), from the epidermis to dermis. Each point shows the mean ± S.E. of three 
experiments. 
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Fig. 1-11. Skin concentration of PABA after an 8 h in vitro skin permeation experiment. Each 
column represents the mean ± S.E. of three experiments. *: P < 0.05 significantly different 
from the epidermis to dermis (Student’s t-test). 
 
1.4. Discussion 
The general concept of delivering the skin tissue is by topical application. Very 
limited studies have emphasized drug-skin tissue delivering via oral administration. The issue 
to be addressed in this study is that the skin is the largest organ in our body and it is not 
always suitable to distribute an active ingredient over the whole area of the skin especially 
for certain indications. Hence, it is necessary to develop oral-skin tissue delivery systems that 
can effectively deliver a drug to a wide area of skin. Recent studies have shown successful 
development of LC formulations that can be applicable for i.v. administration [32, 33]. A 
previous study [32] has demonstrated that PHT dispersions could trigger complement 
activation, and the process may limit their use for i.v. administration as this may initiate 
infusion-related reactions in sensitive individuals. However, complement activation was 
significantly milder when PHT was replaced with GMO. These finding should be considered 
for the safety concerns of such materials. Minimal studies have been undertaken to 
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investigate potential toxic effects of nanoparticle formulations made from LC forming lipids 
[34-36]. GMO was reported as a nontoxic, biodegradable and biocompatible material 
classified as GRAS (generally recognized as safe), and it is included in the FDA Inactive 
Ingredients Guide and in non-parenteral medicines licensed in the UK [37]. Its 
biodegradability comes from the fact that GMO is subject to lipolysis due to diverse kinds of 
esterase activity in different tissues [38-40]. In contrast, PHT comprises of a trihydroxy head 
group and a branched phytanyl tail without the presence of a labile (e.g. ester) functionality, 
which may confer more stable toward enzymatic degradation [41, 42]. A previous study has 
showed that the in vitro toxicity of PHT cubosomes is considerably greater than that of GMO 
cubosomes. The increased toxicity of PHT appears to result from its greater ability to disrupt 
the cellular membrane and oxidative stress [42]. No toxicity studies have been reported to 
investigate the toxic effect of MGE cubosomes. Further efforts are necessary to investigate 
the potential toxicity of such materials for therapeutic applications. 
In the present study, I evaluated LC forming lipids formulations as an orally 
administered drug delivery system for skin tissue delivering. I initially prepared PABA oral 
formulations using different types of LC forming lipids. The phase behavior of these 
formulations was determined by SAXS measurement, based on international tables for 
crystallography [30, 31] obtained reflection patterns for dispersed PABA-GMO formulation 
at √2, √3, √4, √6, √8, √9 (Fig. 1-3a), PABA-PHT formulation at √2, √3, √4, √6, √8, √9 (Fig. 
1-3b) and PABA-MGE formulation at √2, √3, √4, √6, √8, √9 (Fig. 1-3c), thereby confirming 
the presence of inverse bicontinuous cubic (V2) Pn3m phase for the prepared formulations 
(Table 1-2). These results are consistent with previous studies on GMO and PHT [43-45]. In 
addition, the obtained lattice parameters (a) of PABA-GMO formulation (Fig. 1-3a) and 
PABA-PHT formulation (Fig. 1-3b) are consistent with other studies on GMO and PHT [46, 
47]. In case of MGE (Fig. 1-3c), no studies were reported on its formulations phase behavior.     
The particle sizes of the LC formulations with or without PABA were measured at 
25°C and 37°C. The obtained data showed that the particle size was not affected by changes 
in temperature or the presence of PABA dispersion (Table 1-3). Although the particle size of 
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the GMO formulation with or without PABA was smaller compared with other LC 
formulations, the details were unknown.  
The viscosity grade of LC forming lipids and their PABA formulations was 
dramatically decreased at physiological temperature (37°C) except for MGE and its PABA 
formulation, which showed almost similar grades at 25°C and 37°C (Table 1-4). The reason 
why the viscosity grade of GMO at 25°C was expressed as >10,000 mPa.s was due to the 
viscometer allowing a sensitive determination of viscosity within a range of 0.3-10,000 
mPa·s. These results suggested that MGE is more thermally stable than GMO and PHT LC 
forming lipids. 
In vitro dialysis release studies showed that there were no changes in the release 
profiles of PABA in PBS pH 7.4 (Fig. 1-4a) and in 0.1 M HCl (Fig. 1-4b), suggesting that 
changes in the physiological GI tract pH do not affect the release behavior of PABA. The 
amount of PABA released from its GMO and MGE formulations was 81 ± 3 and 90 ± 4%, 
respectively, against a dose at 240 min. In case of PABA-PHT formulation, PABA release 
was slower than that from the PABA solution or other PABA-LC formulations and the 
amount of PABA released was 67 ± 2% at 240 min. These results suggested that the high 
viscosity of PHT at 37°C could affect the drug mobility in its formulation and its release rate. 
High correlation coefficients were obtained for each formulation as shown in Table 1-5, 
which indicated that in vitro drug release profiles of PABA cubosomes were fitted well with 
the square root Higuchi model. The obtained two phases of PABA release suggested a 
proposed diffusion mechanism that PABA tends to be adsorbed at the surface of LC during 
the fast release phase (5-60 min), followed by a slow release phase (60-240 min) of PABA 
from the LC-matrix. In-depth investigations, the short time taken to achieve more than 50% 
release of PABA from its LC formulations justifies that these systems are a burst release 
delivery system where drug is released by diffusion from the cubic phase matrix. Other 
studies also showed that cubosomes should be classified as a burst release delivery system 
[8, 48]. 
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In vivo studies have shown that the bioavailability of PABA was significantly 
improved by administration of PABA-LC formulations compared with PABA solution alone 
(Fig. 1-6 and Table 1-6). The Cmax after oral administration of dispersed PABA-MGE (36 ± 
3.7 nmol/mL) or -GMO (27 ± 2.4 nmol/mL) formulation was significantly higher than PABA 
solution (13 ± 2.3 nmol/mL). The Tmax after administration of dispersed PABA-MGE (26 ± 
9 min) formulation was relatively faster compared with PABA solution (33 ± 5 min) and the 
PABA-GMO (38 ± 5 min) and -PHT (30 ± 8 min) formulations. In addition, the 
bioavailability of PABA was significantly improved by administration of dispersed PABA-
MGE (91 ± 13%) or -GMO (78 ± 3%) formulations compared with PABA solution (19 ± 
2%). Although the PABA-PHT formulation exhibited significantly improved bioavailability 
(62 ± 10%), no significant improvement in Cmax was obtained compared with those for PABA 
solution and the other formulations. No plasma concentration was observed 6 h after 
administration except for the PHT formulation, in which a very low concentration of PABA 
(3 ± 1 nmol/mL) was observed at 8 h (not showed in Fig. 1-6). These results suggested that 
the PABA-MGE formulation was the most efficient formulation for enhancing Cmax and the 
bioavailability of PABA. Although the PABA-PHT formulation managed to sustain PABA 
concentration even at 6 h after administration, the Cmax was not improved compared with the 
PABA solution only. In addition, the obtained results suggested that changes in the 
bioavailability can be observed dependent on the individual LC forming lipid used in the 
formulation (Fig. 1-6). Further investigations was done to examine the effect of the 
physiological temperature, viscosity and the emulsifying effect of the stomach on the 
bioavailability of PABA. The PABA-PHT formulation showed the highest viscosity at 37°C 
compared with the other formulations, which was consistent with the high percentage of 
PABA remaining in the stomach with this formulation compared with the other PABA-LC 
formulations (Fig. 1-9). Because the emulsifying ability of the stomach is well known [45], 
the obtained results suggested that the high viscosity of PHT could delay the emulsifying rate 
of the PABA formulation in the stomach and consequently could prolong the absorption rate 
and stomach emptying rate of the dispersed drug. This could be a reason why it managed to 
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sustain the release of PABA for longer hours but with relatively low bioavailability and Cmax 
compared with the other formulations. 
The other LC forming lipids used in this study was GMO, which is one of the most 
widely studied LC forming lipids [49]. The present findings showed that the physical state 
of GMO can be easily affected with the changes in temperature and the viscosity of this LC 
forming lipid and its PABA formulation was dramatically decreased at 37°C. In addition, the 
amount of PABA remaining in the stomach using GMO was low compared with the PABA-
PHT formulation. These results suggested that this formulation can be emulsified by the 
stomach at a faster rate compared with PABA-PHT, and this might offer better drug mobility 
and influence the movement and absorption of the drug in the intestine. Therefore, it 
significantly improved bioavailability and Cmax compared with PABA solution. At the same 
time, the high viscosity of this LC forming lipid at 25°C makes it not easy to handle, not 
practical for drug loading and need to melt at 50°C before its use. 
In the case of MGE, no studies have utilized this for oral drug delivery. The present 
finding showed that MGE was more thermally stable compared with other LC forming lipids. 
The PABA-MGE formulation showed the highest bioavailability and Cmax and relatively 
short Tmax compared with PABA solution and other LC formulations. The low viscosity of 
MGE at 37°C might offer more drug mobility and drug absorption from the intestine, and 
this was consistent with the low amount of PABA remaining in the stomach compared with 
PABA-PHT the formulation (Fig. 1-9), at the same time its low viscosity at 25°C makes it 
easy to handle and more practical for drug loading.  
In consequence, a non-uniform mixture with gel-like high viscosity aggregates was 
observed in the preparation of the PABA-ERT formulation, which was related to the high 
melting point of ERT, making it impractical for designing an oral formulation; therefore, no 
further work was carried out using this lipid. 
Although a significant improvement in skin concentration was observed with the 
administration of dispersed PABA-GMO or -MGE LC formulations compared with PABA 
solution at 30 min, no significant enhancement in the skin concentration of PABA was 
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observed using PABA-PHT formulation compared with PABA solution (Fig. 1-7a). No 
detection of PABA in the skin was observed 3 h after PABA solution administration. 
However, dispersed PABA-LC formulations maintained a low concentration of PABA in the 
skin even after 3 h (Fig. 1-7b). As a consequence, as shown in Fig. 1-6 and Table 1-6, the 
Cmax of PABA after p.o. administration of its solution or LC formulations was obtained within 
40 min after administration, then the concentration profiles of PABA decreased after 40 min. 
In addition, the skin concentrations at 30 min were higher than those at 3 h after 
administration. These results suggested that the skin concentrations of PABA were closely 
related to its plasma level. 
Moreover, in vitro skin permeation results showed no changes in the skin 
permeation profiles of PABA after application of its solution on the epidermis side or on the 
dermis side (Fig. 1-10). However, skin concentration of PABA was significantly higher after 
its application on the dermis side compared with its application on the epidermis side (Fig. 
1-11), indicating that the affinity of PABA for accumulation in the skin via systemic direction 
is higher than its delivery via the topical direction; and this could be due to the high barrier 
function of the stratum corneum. The results obtained in this study advantageously support 
the concept of delivering PABA to skin.  
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1.5. Chapter conclusion 
The present data showed that LC formulations are a promising approach to improve 
the oral absorption and skin tissue delivering of PABA. The PABA-MGE formulation was 
the most efficient formulation for enhancing Cmax, bioavailability and skin tissue delivering 
of PABA compared with other formulations. The plasma concentration profiles can be 
modified based on the type of LC forming lipid used in the formulation design. Despite the 
changes in the plasma concentration profiles that the observed using different LC forming 
lipids, my main intention was to enhance the oral absorption and skin tissue delivering of 
PABA and to evaluate LC formulations for oral drug delivery. Further studies need to be 
conducted to investigate the mechanism of enhancing GI tract-drug absorption using LC 
formulations. Delivering the drug to skin by orally dispersed PABA-LC formulations could 
be a promising achievement in cosmeceutical, dietary and clinical fields.  
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Chapter 2 
A novel chemical enhancer approach for transdermal delivery with C17-monoglycerol 
ester liquid crystal forming lipid 
 
2.1. Introduction 
Transdermal administration of drugs represents an excellent alternative to 
conventional pharmaceutical dosage forms. Transdermal delivery provides convenient and 
pain-free self-administration for patients. It eliminates frequent dosing administration and 
peaks and troughs in plasma level associated with oral dosing and injections to maintain a 
constant drug concentration, so that drugs with a short half-life can be delivered effectively 
by transdermal administration. However, transdermal drug delivery often faces the problem 
of no or insufficient penetration of the active pharmaceutical substances through the skin. 
The outermost layer of skin, the stratum corneum, has a role as the primary barrier against 
water evaporation from the body and drug entry through skin into the body. Thus, 
overcoming the stratum corneum barrier is important to develop transdermal drug delivery 
systems. Chemical approaches, such as penetration enhancers [50] and physical approaches, 
such as iontophoresis [51], phonophoresis [52] and electroporation [53, 54], have been 
evaluated to increase the skin permeation of several drugs. Physical approaches are often 
associated with several disadvantages, such as their requirement for special application 
apparatus and their cost. Therefore, in the present study I aimed to evaluate the chemical or 
formulation approach with skin permeation-enhancing ability using LC formulation. LCs are 
semisolids made of lipids with crystalline structures combining the properties of both crystal 
and liquid states. GMO (Fig. 1-1) is one of the most widely studied LC-forming lipids used 
for topical application, and it is considered the gold standard for developing LC formulations 
[55, 56]. In the present study, I investigated the skin penetration enhancing effect of a novel 
LC-forming lipid, MGE (Fig. 1-1), and the results obtained were compared with those with 
GMO. Although previous studies have provided information on LC formulations for 
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transdermal drug delivery [4, 57], very few studies have focused on the skin penetration-
enhancing ability of LC-forming lipids with different physicochemical properties of drugs. 
GMO is a very well-known self-assembling amphiphilic molecules that form a 
variety of crystalline structures with useful mechanical properties of special interest in drug 
delivery. In the presence of a small amount of water, GMO forms reversed micelles 
characterized by an oily texture [58]. As more water is added, a mucous-like system is formed 
that corresponds to the lamellar phase. GMO forms cubic or hexagonal phases when more 
water is added (20-40%) over a wide temperature range. These phases are highly viscous, in 
the presence of high amounts of water in temperatures ranging from 20-70 C, the cubic and 
hexagonal phases might exist in a stable condition [59, 37]. Previous research has 
demonstrated that the LC phases of GMO such as the cubic and hexagonal phases, increased 
transdermal drug delivery. As a transdermal absorption enhancer, GMO probably acts by 
causing a temporary and reversible disruption of the lamellar structure of the lipid bilayer in 
the stratum corneum and, in this way, increasing intercellular lipid fluidity [60, 61].  
In the present study, I initially prepared LC formulations containing drugs with 
different physicochemical properties (tranexamic acid [TXA], 4-methoxy-salicylic acid [4-
MS], catechin [CC], and calcein [Cal]) (Table 2-1). These formulations were prepared using 
two different types of LC-forming lipids: MGE and GMO. The chemical structures of MGE 
and GMO are showed in Fig. 1-1. As mentioned above, GMO is the most widely studied LC-
forming lipid, but no previous studies have utilized the skin permeation enhancing ability of 
MGE. 
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Table 2-1 Physicochemical properties of the compounds used in the present study. 
 Abbreviation M.W. log Ko/w*  
Tranexamic acid TXA 157.21 -0.3 
4-Methoxy-salicylic acid 4-MS 152.14 0.5 
Catechin CC 290.26 0.8 
Calcein Cal 622.55 -2.02 
* Octanol/water partition coefficient of compounds at pH 7.4 
 
The confirmation of LC phase structures in the prepared formulations was determined 
using a polarizing light microscope and SAXS. The physicochemical measurements of these 
formulations were performed using a viscometer and a Zetasizer. The release of drugs from 
LC formulations was determined using a dialysis release method. The skin penetration-
enhancing ability of LC formulations was also investigated by in vitro skin permeation 
studies.  
 
2.2. Materials and methods 
2.2.1. Materials 
MGE with a normal purity of > 99.56% and GMO with a normal purity of > 97% 
were obtained from Farnex Co., Inc. (Yokohama, Japan). TXA was purchased from Sigma 
Aldrich (St. Louis, MO, USA). 4-MS, CC, and Cal were purchased from Tokyo Chemical 
Industry Co., Ltd. (Tokyo, Japan). Other reagents and solvents were of special grade or HPLC 
grade and used without further purification. 
 
2.2.2. Preparation of LC formulation 
Table 2-2 shows the composition of LC formulations prepared in this study (for 
chapter 2). These formulations were designed based on a 1:1 ratio of the active ingredient in 
distilled water (drug solution) and LC-forming lipids. GMO was melted at 70°C before use, 
but MGE was dispersed with drugs solution without preheating. The mixture was dispersed 
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using a microsyringe dispenser (250 µL-syringe) (Ito Corporation, Shizuka, Japan). 
 
Table 2-2 Composition of dispersed TXA-, 4-MS-, CC-, and Cal-LC formulations. 
Formulation  Drug concentration % Drug solution % MGE  % GMO 
TXA-MGE 19 mM 50 50 --- 
4-MS-MGE 1 mM 50 50 --- 
CC-MGE 10 mM 50 50 --- 
Cal-MGE 3 mM 50 50 --- 
TXA-GMO 19 mM 50 --- 50 
4-MS-GMO 1 mM 50 --- 50 
CC-GMO 10 mM 50 --- 50 
Cal-GMO 3 mM 50 --- 50 
 
 
2.2.3. Polarizing light microscopic examination 
 
The LC samples were observed using a polarizing light microscope (Olympus IX71, 
Tokyo, Japan). A pin-tip amount of the LC-forming lipid or LC formulation was smeared 
onto a microscope glass slide using a microsyringe dispenser and then quickly covered with 
a cover slip. The microsyringe containing LC-forming lipid or LC formulation was slowly 
pressed over the glass slide to make it as thin as possible. GMO was melted at 70°C before 
pressing it over the glass slide, but MGE was pressed without preheating. A 40× objective 
lens and 10× eyepiece lens were used with cross polarizers in the bright field to detect 
birefringence. Micrographs were taken using the polarizing microscope. 
 
2.2.4. Measurement of particle size and zeta potential 
The particle size and zeta potential of LC formulations were determined using a 
dynamic light scattering Nano-ZS ZEN3600 Zetasizer (Malvern Instruments Ltd., 
Worcestershire, UK). LC samples were diluted in water and shaken using a vortex mixer 
prior to measurement. Following the particle size analysis of the LC formulations, the mode 
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was switched from ‘‘Size’’ to ‘‘Zeta,’’ and the zeta potential of the LC formulations was 
recorded. Each measurement for the particle size and zeta potential was repeated three times.    
 
2.2.5. Measurement of viscosity 
The viscosity of LC-formulations was measured using a viscometer (Toki Sangyo 
Co., Ltd., Tokyo, Japan) that allowed a sensitive determination of viscosity within a range of 
0.3–10,000 mPa·s with an accuracy of 1% relative error. 
 
2.2.6. SAXS measurement 
SAXS measurement of LC-formulations was performed using a Nano-Viewer 
(Rigaku, Tokyo, Japan) with a Pilatus 100K/RL 2D detector. The X-ray source was Cu Kα 
radiation with a wavelength of 1.54 Å and operating at 45 kV and 110 mA. The sample-to-
detector distance was set at 375 mm. Each sample was placed into a vacuum-resistant glass 
capillary cell and exposed at 25C for 10 min. The SAXS pattern obtained was plotted against 
the scattering vector length,    ,2/sin/4 q where   is the scattering angle. 
 
2.2.7. Release study 
A dialysis membrane (molecular weight cut-off; 2,000–14,000 Da) (Sanko Junyaku 
Co., Tokyo, Japan) was set in a vertical-type diffusion cell (effective diffusion area: 0.95 
cm2) and the receiver chamber was maintained at 32°C. Phosphate-buffered saline (PBS; pH 
7.4) was applied to the receiver chamber for TXA, 4-MS, and CC, and PBS containing 1.0 
mM EDTA·2Na was used for Cal. Drug solution (1.0 mL) or its LC formulation (300 mg) 
was applied to the donor cell to start the release experiment. An aliquot (500 µL) was 
withdrawn from the receiver chamber, and the same volume of PBS or 1.0 mM EDTA·2Na 
was added to the chamber to keep the volume constant. The amount of TXA, 4-MS and CC 
released was determined using an HPLC (Shimadzu Ltd., Kyoto, Japan). In case of Cal, the 
amount released was determined using a fluorescence spectrophotometer (Shimadzu Ltd., 
Japan). The cumulative % drug release was plotted against the square root of time (Higuchi’s 
law) [29]. 
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2.2.8. Animals 
Male hairless rats (8 weeks old) were purchased either from Life Science Research 
Center, Josai University (Sakado, Saitama, Japan) or Ishikawa Experiment Animal 
Laboratories (Fukaya, Saitama, Japan). Animals were housed in temperature-controlled 
rooms (25 ± 2C) with a 12 h light-dark cycle (07:00–19:00 h). The rats were allowed free 
access to food (Oriental Yeast Co., Tokyo, Japan) and tap water. The animal experiment 
protocol was approved by the Animal Care and Use Committee of Josai University (Sakado, 
Saitama, Japan). 
 
2.2.9. In vitro skin permeation study 
Full-thickness hairless rat skin was excised from the abdomen under anesthesia by 
i.p. injection of three types of anesthesia (medetomidine, 0.375 mg/kg; butorphanol, 2.5 
mg/kg; and midazolam, 2 mg/kg). The excess fat was trimmed off and the skin samples were 
set in vertical-type diffusion cells (effective diffusion area: 0.95 cm2) with the epidermis side 
facing the donor compartment. PBS (pH 7.4) with or without 1.0 mM EDTA·2Na was applied 
to the receiver chamber as in the release experiment and maintained at 32°C. These skin 
permeation experiments were conducted after hydration for 60 min with PBS with or without 
1.0 mM EDTA·2Na. Drug solution (1.0 mL) or its LC-formulation (300 mg) was applied to 
the donor cell to start the in vitro skin permeation experiment. An aliquot (500 µL) was 
withdrawn from the receiver chamber, and the same volume of PBS with or without 1.0 mM 
EDTA·2Na was added to the chamber to keep the volume constant. The skin permeation of 
TXA, 4-MS and CC permeated through skin was determined by HPLC, and that of Cal was 
determined using a fluorescence spectrophotometer. 
 
2.2.10. HPLC conditions 
The same volume of acetonitrile containing parabens was added to TXA, 4-MS and 
CC samples. After gentle mixing, the sample was centrifuged for 5 min at 21,500 × g and 
4°C to remove proteins and contaminants. The supernatant was injected onto the HPLC. The 
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HPLC system consisted of a pump (LC-10AD; Shimadzu, Kyoto, Japan), Chromatopac (C-
R6A; Shimadzu), UV detector (SPD-6A; Shimadzu), system controller (SCL-6B; Shimadzu), 
and auto-injector (SIL-7A; Shimadzu). The LiChroCART®250-4 column (KGaA·64271; 
Merck, Darmstadt, Germany) was maintained at 40°C during the eluting mobile phase, 0.1% 
phosphoric acid:acetonitrile = 75:25 for TXA, 0.1% phosphoric acid:acetonitrile = 55:45 for 
4-MS, and 0.1% phosphoric acid containing 5 mM sodium dodecyl sulfate:acetonitrile = 
50:50 for CC. The flow rate was adjusted to 1.0 mL/min. The injection volume was 20 μL, 
and detection was performed at 220 nm for TXA, 230 nm for 4-MS and 245 nm for CC.  
 
2.3 Results 
2.3.1 Polarizing light microscopic examination 
Figures 2-1 and 2-2 shows samples observed using a polarizing light microscope. No 
optical anisotropy was observed in cases of MGE and GMO alone (a, b), because these lipids 
cannot form crystalize structures without excess amount of water. In case of MGE- and 
GMO-LC formulations, they showed clear optical anisotropy on the displayed image (c, d, e, 
f, g, h, i, j). Moreover, these formulations appeared as uniform opaque ointment-like mixtures 
with no visible signs of aggregates. 
In general, if there was any materials with high birefringence, the light output by the 
top layer, a linear polarizer, may cause optical anisotropy to appear on the displayed image, 
depending on the orientation of the viewer with respect to the display. These results showed 
that the present LC formulations were managed successfully to form crystallized 
formulations because of high birefringence with the polarizing light microscope. 
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Fig. 2-1. LC-forming lipids or LC formulations upon application under polarized 
microscope: (a), MGE alone; (b), GMO alone; (c), TXA-MGE formulation; (d), 4-MS-MGE 
formulation; (e), CC-MGE formulation; (f), Cal-MGE formulation. The optical anisotropy 
confirming the presence of LC in the prepared formulation.  
MGE alone 
 
GMO alone 
TXA-MGE 4-MS-MGE 
CC-MGE 
Cal-MGE 
200 µm 200 µm 
200 µm 200 µm 
200 µm 200 µm 
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Fig. 2-2. LC-forming lipids or LC formulations upon application under polarized 
microscope: (g), TXA-GMO formulation; (h), 4-MS-GMO formulation; (i), CC-GMO 
formulation and (j), Cal-GMO formulation. The optical anisotropy confirming the presence 
of LC in the prepared formulations. 
 
 
 
 
 
 
TXA-GMO 
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CC-GMO 
Cal-GMO 
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2.3.2. SAXS chart of LC formulations 
The phase structure of TXA-, 4-MS- and CC-MGE and GMO formulations was 
evaluated by SAXS. Figure 2-3 shows the X-ray diffraction profiles of all the formulations. 
The typical reflection patterns at nearly 1, √3, and √4 revealed the presence of a hexagonal 
phase (H1, H2) in all prepared formulations (a-d) (e-h in Appendix / Supplementary data) [30, 
31]. These results confirmed that both MGE- and GMO-LC formulations managed to form 
hexosomes successfully.  
      
Fig. 2-3. SAXS charts of LC formulations. 
(a), TXA-MGE formulation; (b), 4-MS-MGE formulation; (c), CC-MGE formulation; (d), 
Cal-MGE formulation; (e), TXA-GMO formulation; (f), 4-MS-GMO formulation; (g), CC-
GMO formulation and (h), Cal-GMO formulation. The reflection patterns at: 1, √3, √4 
confirming the presence of a hexagonal phase (H1, H2) for all prepared formulations (a-d) (e-
h in Appendix / Supplementary data). 
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2.3.3. Measurement of particle size and zeta potential 
The particle size and zeta potential of LC formulations were determined immediately 
(Fig. 2-4a, b) and 10 days (Fig. 2-4c, d in Appendix / Supplementary data) after their 
preparation. The results showed that both MGE- and GMO-LC formulations had small 
particle sizes ranged between 220 and 280 nm, and the zeta potential of these formulations 
was ranged between -17 and -30 mV. In addition, no significant changes were observed in 
particle size or zeta potential at 10 days after their preparation.  
 
Fig. 2-4. Particle size (a, c) and zeta potential (b, d) of LC formulations immediately (a, b) 
and 10 days (c, d in Appendix / Supplementary data) after preparation. Each point represents 
the mean ± S.E. of three experiments. 
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2.3.4. Measurement of viscosity 
The viscosity of LC formulations was measured using a viscometer. Figure 2-5 shows 
the obtained viscosity values. These values were affected dramatically by the type of LC-
forming lipids used in the preparation. The viscosity values of LC formulations with MGE 
were significantly lower than those with GMO. These results showed that MGE-LC-
formulations has lower viscosity than GMO-LC-formulations, and its low viscosity made it 
easy to handle and more practical for drug loading. GMO requires melting at 70°C before its 
use for formulation preparation, but MGE was dispersed with drug solution without 
preheating owing to its low viscosity. 
Fig. 2-5. The apparent viscosity of LC formulations.  
Each point represents the mean ± S.E. of three experiments.*: P < 0.05 significantly different 
from MGE-LC formulation (Student’s t-test). 
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2.3.5. Drug release properties from LC formulations 
The release study was performed using a vertical-type diffusion cell. Figure 2-6 
shows the release profile of TXA, 4-MS, CC and Cal from their MGE and GMO formulations. 
All profiles were obeyed to Higuchi’s law [29]. The amounts of TXA, 4-MS, CC and Cal 
released from MGE formulations were 13.9 ± 2.5%, 23.7 ± 3.2%, 16.7 ± 2.8%, and 9.6 ± 
0.8%, respectively, against the initial dosing. In the case of GMO formulations, the amounts 
of TXA, 4-MS, CC and Cal released were 7.3 ± 1.6%, 14.4 ± 2.2%, 10 ± 1.8% and 6.1 ± 
0.9%, respectively, against the initial dosing. These results might be related to the high 
viscosity of GMO-LC formulations and thus could affect the drug diffusivity and the release 
rate. 
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Fig. 2-6. Release profiles of TXA (a), 4-MS (b), CC (c) and Cal (d) from their LC 
formulations. Symbols: (a): (■), TXA-MGE formulation; (□), TXA-GMO formulation; (b): 
(●), 4-MS-MGE formulation; (○), 4-MS-GMO formulation; (c): (▲), CC-MGE formulation; 
() CC-GMO formulation; (d): ( ), Cal-MGE formulation; ( ), Cal-GMO formulation. 
Each point represents the mean ± S.E. of three experiments. 
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2.3.6. Skin permeation of drugs from LC formulations 
Figure 2-7 shows the effect of MGE and GMO formulations on the time course of the 
cumulative amount of TXA, 4-MS, CC, and Cal that permeated through hairless rat intact 
skin. Significant improvements in skin permeation of TXA, 4-MS, and CC were observed 
after application their MGE and GMO formulations compared with that permeated from drug 
solution (dissolved in water). The enhancement skin permeation ratios for TXA-, 4-MS-, CC-, 
and Cal-MGE formulations were 4.6, 3.5, 4.2, and 5.5, respectively, and those for TXA-, 4-
MS-, CC-, and Cal-GMO formulations was 2.5, 2.6, 3.1, and 3, respectively. These results 
clearly showed that MGE formulations had better skin permeation enhancement effect 
compare with GMO formulations. 
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Fig. 2-7. Effect of LC formulation on the time course of the cumulative amount of TXA (a), 
4-MS (b), CC (c) and Cal (d) that permeated through hairless rat intact skin.  
Symbols: (a): ( ), TXA solution; (■), TXA-MGE formulation; (□), TXA-GMO formulation; 
(b): ( ), 4-MS solution; (●), 4-MS-MGE formulation; (○), 4-MS-GMO formulation; (c): 
( ), CC solution; (▲), CC-MGE formulation; () CC-GMO formulation; (d): ( ), Cal 
solution; ( ), Cal-MGE formulation; ( ), Cal-GMO formulation. Each point represents the 
mean ± S.E. of three experiments. *: P < 0.05 significantly different from drug solution 
(Student’s t-test). 
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2.4. Discussion 
LC-forming lipids represent an important class of biocompatible amphiphiles, and 
their application extends to several fields, such as cosmeceutical, dietary and pharmaceutical 
technologies [38]. In recent years, the LC phases formed by LC-forming lipids have been 
shown to be able to accommodate biologically active molecules such as vitamins, enzymes 
and other proteins [62-64]. This ability opens new possibilities for pharmaceutical 
applications. Previous researches have demonstrated that the LC phases, such as cubic and 
hexagonal phases, increased transdermal drug delivery [4, 65]. The advantages of LC 
formulations for transdermal drug delivery systems might include biocompatibility and the 
ability to self-assemble their structure [12].  
In the present study, we investigated the usefulness of MGE-LC as a new skin 
permeation enhancing approach, and the obtained results were compared with GMO as one 
of the most widely studied LC-forming lipids used in topical formulations.  
TXA, 4-MS and CC drug models were selected due to their topical therapeutic 
beneficial. Topical application of TXA to bleeding wound surfaces can reduce the blood loss. 
4-MS can be used to treat skin conditions that involve scaling or overgrowth of skin cells 
such as psoriasis, ichthyoses, corns, calluses and warts on the hands or feet. CC can inhibit 
skin tumorigenesis, reducing inflammation, protecting skin from UV-induced various 
damages and inhibiting formation of melanin. However, these drug models have low 
transdermal absorption [66, 67]. Moreover, Cal has low transdermal absorption because of 
its hydrophilicity and large molecular weight. Therefore, TXA, 4-MS, CC and Cal were 
selected as drug models for skin studies.   
We prepared LC formulations using MGE and GMO containing drugs based on a 1:1 
ratio, as shown in Table 2-2. These formulations were prepared by extruding lipid dispersion 
50 times with a microsyringe dispenser, to incorporate high percentage of lipid (50%) with 
the drug solution (50%). This technique has an advantage by mixing high concentration of 
lipid up to 50% with the drug solution without the aid of dispersant. Non-uniform mixtures 
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with high viscus aggregate were observed using other techniques such as homogenizer and 
ultrasonic even in the presence of dispersants.    
Birefringence was investigated for the prepared formulations using a polarizing light 
microscope. As a result, TXA-, 4-MS-, CC- and Cal-MGE and GMO formulations showed 
a clear optical anisotropy on the images; however, no optical anisotropy was observed in the 
case of MGE and GMO alone (Fig. 2-1a, b). These results strongly suggested that both MGE 
and GMO formulations managed to form crystalline formulations successfully because of 
the high birefringence of these formulations.  
Furthermore, the phase structure of the formulations was examined by SAXS, and the 
results showed that typical reflection patterns at nearly 1, √3, and √4 for both MGE and GMO 
formulations revealed the presence of a hexagonal phase (H1, H2) (Fig. 2-3a-d) (Fig. 2-3e-h 
in Appendix / Supplementary data). The driving force of forming hexosome systems is the 
physically applied shear stress by microsyringe dispensers.  
The critical packing parameter (CPP) is useful in predicting which phases can be 
preferentially formed by a given lipid. When CPP < 1, oil-in-water self-assembled structures 
form, such as normal micelles, normal cubic structure, and normal hexagonal phases. When 
CPP > 1, water-in-oil self-assembled structures form, such as reversed micelles, reversed 
cubic structure, and reversed hexagonal structure [8]. Additives or active ingredients might 
affect CPP as well as the LC phase structure. Generally, GMO formed the invert-type LC 
with CPP > 1 [58]. No previous studies have performed on the effect of CPP on the LC phase 
structure formed by MGE.  
Previous studies have reported that the hexagonal phase presents some advantages. It 
has a larger surface area to interact with the skin, high fluidity, and can be incorporated into 
compounds independently of their solubility [68, 69]. Although a hexagonal phase (H1, H2) 
was formed in all prepared formulations, factors such as concentration of lipid and drug could 
influence the phase transition of these formulations. Further studies are necessary to be 
conducted to understand the effect of such factors on the phase transition of LC formulations.    
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The particle size and zeta potential of MGE- and GMO-LC formulations were 
determined immediately (Fig. 2-4a, b) and at 10 days after preparation (Fig. 2-4c, d in 
Appendix / Supplementary data). The obtained data showed that these formulations had small 
particle size (220-280 nm) and the zeta potential ranged between -17 and -30 mV. In addition, 
no significant changes were observed in the particle size or zeta potential measurements at 
10 days after preparation. These results suggested that the present MGE and GMO 
formulations had small particle size with high surface charges and electrical repulsion 
between the particles, and thus their aggregation was prevented even 10 days after 
preparation. The zeta potential presented strong negative values for all the analyzed samples, 
indicating the predominance of repulsive forces. The reason why LC formulations showed 
negative zeta potential values is due to the present of free oleic acid in the lipid phase may 
give rise to the negative charge of the particles. In addition, the negative charge can also be 
explained by preferential adsorption of hydroxyl ions at the lipid-water interface.  
These results were consistent with previous findings on the zeta optional of LC 
formulations [70]. 
Furthermore, the viscosity of the formulations was measured. The viscosity of LC 
formulations with MGE was significantly lower than those with GMO. In contrast to MGE, 
the high viscosity of GMO makes it less easy to handle, impractical for drug loading, and 
requires melting at 70°C before use. These results suggested that the type of LC-forming 
lipid dramatically affected the viscosity of the formulation (Fig. 2-5). In consequence, the 
drug release results showed that the low viscosity of MGE-LC-formulations could influence 
the drug diffusivity and the release rate of the entrapped drugs in these formulations (Fig. 2-
6). In general, hydrophilic drugs are tended to be located close to the polar head of lipid or 
in the water channels (water phase), whereas lipophilic drugs will be loaded in the lipid 
bilayer and amphiphilic drugs in the interface (lipid phase). The aqueous and lipid phases in 
the present formulation design were in a ratio 1:1, therefore, these formulations can 
accommodate a wide range of different physicochemical drugs. The obtained release profiles 
suggest that the viscosity of hexagonal is the decisive factor mainly influenced of drug 
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diffusion in LC-formulations. The low viscosity of MGE could be related to the chained-
liked terpenes and double bound in its structure (Fig. 1-1). 
In vitro skin permeation experiment was carried out using hairless rat skin. 
Correlation of skin permeation of chemicals to human skin is very important and previous 
studies showed a good relationships of skin permeation of chemicals between human and 
hairless rat skin [71, 72]. Significant improvement in the skin permeation of different drugs 
was observed after application of MGE and GMO formulations (Fig. 2-7). The enhancement 
of the skin permeation ratio of MGE formulations was higher than those of GMO 
formulations. These results clearly showed that MGE formulations managed to improve the 
skin permeation enhancement effect compared with GMO formulations. These findings 
could be related to the low viscosity of MGE formulations, and this might offer better drug 
diffusivity and influence the movement and permeation of the drugs in and across the skin. 
The detailed mechanism of the skin permeation enhancing ability by LC systems is not fully 
understood [73]. It was speculated that cubic structure with similar nano-structure as the skin, 
increases the interaction between skin and formulation and enhances the skin permeation [74, 
75]. A previous study [76] reported that the hexagonal phase may facilitate the fusion of LCs 
with the stratum corneum and deeper skin layers and thereby may improve drug delivery to 
the skin. Moreover, the hexosome system, owing to its larger surface area to interact with the 
skin and high fluidity, can be incorporated into compounds independently of their solubility 
[68, 69]. Further studies are needed to clarify the mechanism and effect of LC phase structure 
on the skin permeation of drugs.  
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2.5. Chapter conclusion  
The present study confirmed that both MGE- and GMO-LC-forming lipids shared the 
same behavior in terms of their birefringence index, LC phase structure, particle size and zeta 
potential. Both the MGE- and GMO-LC formulations managed to improve skin permeation 
of various physicochemical properties of the drugs. However, MGE formulations had lower 
viscosity, faster drug release and better skin permeation than GMO formulations. The results 
in the second chapter strongly suggested that the low viscosity of MGE-LC-formulations 
might influence drug diffusivity and permeability through skin. The present MGE-LC 
forming lipid can be utilized as a promising new topical formulation for therapeutic drugs 
and cosmetic ingredients. 
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Chapter 3 
Designing and optimizing of liquid crystal formulations for oral administration and 
transdermal application 
 
3.1. Introduction 
As previously stated, increasing attention has been paid to LC formulations, such as 
cubosomes and hexosomes, because of their remarkable structural complexity and usefulness 
in various pharmaceutical applications. LC-forming lipids represent an important class of 
biocompatible amphiphiles, and their application extends to several fields, such as 
cosmeceutical, dietary, and pharmaceutical technologies [38, 12]. LC phases are able to 
accommodate biologically active molecules such as vitamins, enzymes, and other proteins 
[63, 64]. The advantages of LC formulations as a drug-delivery system are their high 
biocompatibility and the self-assembly ability of their structure. This ability opens new 
possibilities for pharmaceutical applications [8]. Several studies have reported the usefulness 
of LC formulations to enhance the drug absorption after oral and transdermal application [57, 
77]. Ali et al. reported enhancing effect of orally administered poorly water soluble drugs of 
spironolactone (estimated log Koctanol/water: 2.9 and molecular weight (MW): 417) and 
nifedipine (estimated log Koctanol/water: 2.2 and MW: 346) with reverse bicontinuous cubic 
phase of monoolein [78]. Nguyen et al. investigated the ability of nanostructured reverse 
bicontinuous cubic phase of monoolein to sustain the absorption of a poorly water soluble 
drug, cinnarizine (estimated log Koctanol/water: 5.8 and MW: 369) after oral administration [28].  
In addition, Cohen-Avrahami et al. examined skin permeation-enhancement effect of a 
hydrophilic drug, sodium diclofenac (log Koctanol/water:  -0.1 and MW: 318) with reversed 
hexagonal lyotropic LC containing a skin permeation enhancer [79]. Lopes et al. investigated 
transdermal delivery of cyclosporin A (log Koctanol/water: 2.92 and MW: 1202) with reverse 
cubic and hexagonal phase of monoolein and also reported another successful application 
with the combination of vitamin K (estimated log Koctanol/water: 11.7 and MW: 451) and 
hexagonal phase of monoolein [65]. Furthermore, in previous studies from our laboratory 
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[61, 4], successful improvement was demonstrated in the drug absorption after oral and 
transdermal application with LC formulations that composed with MGE (Fig. 1-1), and the 
enhancement effect of these formulations was dramatically affected by the type of LC-
forming lipids.  MGE was easy-to-handle due to its low viscosity at 25 °C compared to GMO 
and PHT and showed better drug absorption enhancement effects. However, no studies have 
investigated the effect of several factors such as physicochemical properties of the entrapped 
drugs and concentration of LC-forming lipids and LC phase structure on the enhancement 
effect of orally and topically administered drugs. Therefore, in the present study, MGE was 
selected as an LC-forming lipid. PABA and its prodrugs, methyl p-aminobenzoate (M-PABA) 
and ethyl p-aminobenzoate (E-PABA) (Table 3-1) were selected as drug models with 
different lipophilicities to understand the effect of the lipophilicity changes on the drug 
absorption performance of LC formulations. On the other hand, for transdermal LC 
formulations, only hydrophilic sodium fluorescein (Na-FL) was selected as a model drug and 
was entrapped with different concentrations of MGE. Overcoming the stratum corneum 
barrier to cutaneously deliver hydrophilic drugs is one of the major challenges in the field of 
dermatologic therapy; therefore, Na-FL was used as a well-known hydrophilic and mal-
absorbed model drug in this study. Thus, in the present study I aimed to develop strategies 
for designing and optimizing oral and topical LC formulations by evaluating the effect of 
these factors on the drug absorption from LC formulations.  
 
Table 3-1 Physicochemical properties of the compounds used in the present study. 
 Abbreviation M.W. ClogP 
p-Amino benzoic acid PABA 137.14 0.98 
Methyl p-aminobenzoate M-PABA 151.17 1.39 
Ethyl p-aminobenzoate E-PABA 165.19 1.93 
Sodium fluorescein Na-FL 376.27 -2.02 
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3.2. Materials and methods 
3.2.1. Materials 
MGE (purity: > 99.56%) was obtained from Farnex Co., Inc. (Yokohama, Japan). 
PABA, M-PABA and E-PABA were purchased from Kanto Chemical Co., Inc. (Tokyo, 
Japan). Na-FL was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). A 
surfactant, Pluronic® F127, was purchased from Sigma-Aldrich (St. Louis, MO, USA). Other 
reagents and solvents were of special grade or HPLC grade and used without further 
purification. 
 
3.2.2. Preparation of oral and topical LC formulations 
Table 3-2 lists the oral and topical LC formulations used in this study. These 
formulations were designed based on changing the concentration of MGE in the formulations 
and entrapped with drugs with different physicochemical properties. The mixture was 
dispersed using a homogenizer (Polytron PT-MR 3000; Kinematica Inc., Littau, Switzerland). 
The dry powder LC formulations were prepared using a freeze dryer (Labcono FZ-18; Asahi 
Life Science Co. Ltd., Tokorozawa, Saitama, Japan). 
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Table 3-2 Composition of oral and topical LC formulations. 
The concentration of PABA, M-PABA, or E-PABA in the formulation was 10 mM and the 
concentration of Na-FL was 5 mM.  
Formulation code: O = Oral formulation; T = Topical formulation; P = PABA; M = M-
PABA; E = E-PABA; F = Na-FL; D = Dry powder; Number = Percentage of MGE. 
*: Rejected oral formulations. 
**: Rejected topical formulations. 
Formulation 
code 
Composition of oral LC formulations 
OP5* PABA solution containing 5% Pluronic® F127 and 5% MGE 
OP10 PABA solution containing 5% Pluronic® F127 and 10% MGE 
OP20 PABA solution containing 5% Pluronic® F127 and 20% MGE 
OP30* PABA solution containing 5% Pluronic® F127 and 30% MGE 
OP10D PABA dry powder formulation containing 5% Pluronic® F127, 10% MGE, 
10% mannitol and 1% ethanol 
OP20D* PABA dry powder formulation containing 5% Pluronic® F127, 20% MGE, 
10% mannitol and 1% ethanol 
OM5* M-PABA solution containing 5% Pluronic® F127 and 5% MGE 
OM10 M-PABA solution containing 5% Pluronic® F127 and 10% MGE 
OM20 M-PABA solution containing 5% Pluronic® F127 and 20% MGE 
OM30* M-PABA solution containing 5% Pluronic® F127 and 30% MGE 
OM10D M-PABA dry powder formulation containing 5% Pluronic® F127, 10% 
MGE, 10% mannitol and 1% ethanol 
OM20D* PABA dry powder formulation containing 5% Pluronic® F127, 20% MGE, 
10% mannitol and 1% ethanol 
OE5* E-PABA solution containing 5% Pluronic® F127 and 5% MGE 
OE10 E-PABA solution containing 5% Pluronic® F127 and 10% MGE 
OE20 E-PABA solution containing 5% Pluronic® F127 and 20% MGE 
OE30* E-PABA solution containing 5% Pluronic® F127 and 30% MGE 
OE10D E-PABA dry powder formulation containing 1% Pluronic® F127, 10% 
MGE, 10% mannitol and 1% ethanol 
OE20D* M-PABA dry powder formulation containing 5% Pluronic® F127, 20% 
MGE, 10% mannitol and 1% ethanol 
TF5** Na-FL solution containing 5% Pluronic® F127 and 5% MGE 
TF10 Na-FL solution containing 5% Pluronic® F127 and 10% MGE 
TF20 Na-FL solution containing 5% Pluronic® F127 and 20% MGE 
TF30 Na-FL solution containing 5% Pluronic® F127 and 30% MGE 
TF40 Na-FL solution containing 5% Pluronic® F127 and 40% MGE 
TF50** Na-FL solution containing 5% Pluronic® F127 and 50% MGE 
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3.2.3. Measurement of particle size and zeta potential 
The particle size and zeta potential of LC formulations were determined using a 
dynamic light scattering Nano-ZS ZEN3600 Zetasizer (Malvern Instruments Ltd., 
Worcestershire, U.K.). LC samples were diluted in distilled water and shaken using a vortex 
mixer prior to measurement.  
 
3.2.4. SAXS measurement 
SAXS measurement of dispersed formulations was performed using a Nano-Viewer 
(Rigaku, Tokyo, Japan) with a Pilatus 100K/RL 2D detector. The X-ray source was Cu Kα 
radiation with a wavelength of 1.54 Å and operating at 45 kV and 110 mA. The sample-to-
detector distance was set at 375 mm. Each sample was placed into a vacuum-resistant glass 
capillary cell and exposed at 25C for 10 min. The SAXS pattern obtained was plotted against 
the scattering vector length,    ,2/sin/4 q where   is the scattering angle. 
 
3.2.5. Release experiment 
A dialysis membrane (molecular weight cut-off; 2,000–14,000 Da, Sanko Junyaku 
Co., Tokyo, Japan) was set in a vertical-type diffusion cell (effective diffusion area: 0.95 
cm2) and the receiver chamber was maintained at 32°C. Phosphate-buffered saline (PBS; pH 
7.4) was applied to the receiver chamber. Drug (PABA, M-PABA, E-PABA or Na-FL) 
solution (1.0 mL) or its LC formulation (1.0 mL) was applied to the donor cell to start the 
release experiment. An aliquot (500 µL) was withdrawn from the receiver chamber, and the 
same volume of PBS was added to the chamber to keep the volume constant. The amount of 
PABA, M-PABA, and E-PABA released was determined using an HPLC (Shimadzu Ltd., 
Kyoto, Japan). In case of Na-FL, the released amount was determined using a fluorescence 
spectrophotometer (Shimadzu Ltd., Kyoto, Japan). The cumulative % of drug released was 
plotted against the square root of time (Higuchi’s plot) [29]. 
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3.2.6. Animals 
Male hairless (WBM/ILA-Ht) and male Wistar (Slc) rats were purchased either from 
Life Science Research Center, Josai University (Sakado, Saitama, Japan) or Ishikawa 
Experiment Animal Laboratories (Fukaya, Saitama, Japan). Animals were housed in 
temperature-controlled rooms (25 ± 2C) with a 12 h light-dark cycle (07:00–19:00 h). The 
rats were allowed free access to food (Oriental Yeast Co., Tokyo, Japan) and tap water. The 
animal experiment protocol was approved by the Animal Care and Use Committee of Josai 
University (Sakado, Saitama, Japan). 
 
3.2.7. HPLC conditions 
The in vivo or in vitro study sample (50 µL) was mixed with the same volume of 
acetonitrile containing methyl paraben (10 µg/mL) as an internal standard and centrifuged (5 
min, 4C). The obtained supernatant (20 µL) was injected into an HPLC system (Shimadzu, 
Kyoto, Japan), which consisted of a system controller (CBM-20A), pump (LC-20AD), auto-
sampler (SIL-20AC), column oven (CTO-20A), UV detector (SPD-M20A) and analysis 
software (LC Solution). The column was an GL Sciences Inc. ODS-3 (5 µm, 4.6 × 250 mm) 
(Nihon Waters K.K., Tokyo, Japan), which was maintained at 40C. The mobile phase was 
acetonitrile : 0.1% phosphoric acid = 8 : 52 (0–4 min), 35 : 65 (4–14 min) and 8 : 92 (14–20 
min). The flow rate was adjusted to 1.0 mL/min. PABA, M-PABA and E-PABA were 
detected at UV 280 nm.  
 
3.2.8. Determination of bioavailability 
Intravenous and oral administrations were performed in Wistar rats under anesthesia 
by intraperitoneal injection of three types of anesthesia (medetomidine, 0.375 mg/kg; 
butorphanol, 2.5 mg/kg; and midazolam, 2 mg/kg) to determine the bioavailability of PABA. 
In case of intravenous administration, PABA dissolved in physiological saline (PABA 
solution) was injected (5.0 µmol/kg) into the tail vein. Blood samples (0.2 mL) were collected 
from the jugular vein at predetermined intervals up to 3 h, and the same volume of saline was 
injected via the tail vein to prevent severe changes in the volume of distribution. For oral 
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administration, PABA solution or LC-formulation (10 µmol/kg) was administered to rats, 
and blood (0.2 mL) was withdrawn from the jugular vein at intervals up to 6 h and the same 
volume of saline was injected via tail vein. Blood samples placed into heparinized tubes were 
immediately separated by centrifugation to obtain plasma (5 min, 4C). Plasma and skin 
samples were stored at -30C until analysis. 
 
3.2.9. In vitro skin permeation experiment 
Full-thickness hairless rat skin was excised from the abdomen under anesthesia by 
i.p. injection of three types of anesthesia as above. Excess fat was trimmed off, and the skin 
samples were set in vertical-type diffusion cells with the epidermis side facing the donor 
compartment. PBS was applied to the receiver chamber as in the release experiment and 
maintained at 32°C. These skin permeation experiments were conducted after hydration for 
60 min with PBS. Drug solution (1.0 mL) or its LC-formulation (1.0 mL) was applied to the 
donor cell to start the in vitro skin permeation experiment. An aliquot (500 µL) was 
withdrawn from the receiver chamber, and the same volume of PBS was added to the 
chamber to keep the volume constant. The skin permeation of Na-FL was determined using 
a fluorescence spectrophotometer. 
 
3.2.10. Determination of AUC 
The area under the plasma concentration–time curve (AUC) was calculated using 
the linear trapezoidal rule. The absolute bioavailability was determined as AUCpo/AUCiv 
using the mean AUC values for oral and intravenous doses.  
 
3.2.11. Statistical analysis 
Statistical analysis was performed using unpaired Student’s t-test (ANOVA), and P 
values less than 0.05 were considered to be significant. 
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3.3. Results  
 
3.3.1. Homogeneity and visible appearance 
 
First, the homogeneity and visible appearance of the prepared LC formulations were 
evaluated. Accepted formulations were a uniform opaque white mixture or uniform powder 
without visible signs of aggregates, whereas rejected formulations appeared as a non-uniform 
dispersion or aggregated wet powder. Figure 3-1 shows photographs to illustrate these criteria 
for accepted and rejected formulations. OP30, OM30, and OE30 (Table 3-2) were 
inconvenient for oral due administration because of the high percentage of lipid (creamy 
formulations); therefore, these formulations were not studied for oral administration. 
However, these formulations were accepted for topical application (TF30 and TF40) (Table 
3-2). Non-uniform mixtures with aggregates were observed with a high percentage of LC-
forming lipid (> 40%); therefore, no further work was carried out with these formulations. 
Fine powders were obtained in OP10D, OM10D, and OE10D (Table 3-2). However, when 
the MGE content increased to 20% (OP20D, OM20D, and OE20D, respectively) (Table 3-
2), aggregated wet powders were observed. Therefore, no further work was carried out with 
them. 
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Fig. 3-1. Illustration photographs of accepted and rejected LC formulations based on 
homogeneity and visible appearance. Accepted formulations were appeared as a uniform 
opaque white mixture or uniform powder without visible signs of aggregates, while rejected 
formulations were appeared as a non-uniform dispersion or aggregated wet powder. 
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3.3.2. Particle size and zeta potential measurement 
Table 3-3 shows particle size and zeta potential values of oral and topical LC 
formulations. The obtained results showed that the particle size tended to be smaller and the 
zeta potential became more negative with increasing MGE content. Formulations with low 
MGE content represented by 5% (i.e., OP5, OM5, OE5, and TF5) tended to have large 
particle size and low negative surface charge. Because the low surface charge indicated low 
stability of the 5% MGE formulations, no further work was carried out with these 
formulations. 
 
Table 3-3 Particle size (nm) and zeta potential (mV) of LC formulations. 
Formulation code Particle size (nm) Zeta potential (mV) 
OP5 409 ± 26 -3.1 ± -0.8 
OP10 340 ± 21 -10.4 ± -1.7 
OP20 288 ± 17 -15.5 ± -2.3 
OP10D 366 ± 27 -10.7 ± -1.4 
OM5 488 ± 23 -2.8 ± -0.7 
OM10 327 ± 14 -11.7 ± -1.3 
OM20 301 ± 29 -16.2 ± -2.4 
OM10D 332 ± 27 -6.9 ± -1.1 
OE5 412 ± 31 -2.6 ± -0.6 
OE10 384 ± 28 -12.4 ± -1.8 
OE20 311 ± 18 -17.6 ± -2 
OE10D 377 ± 27 -7.9 ± -1.2 
TF5 388 ± 22 -3.1 ± -0.7 
TF10 348 ± 12 -12.1 ± -1.5 
TF20 328 ± 26 -17.4 ± -1.3 
TF30 351 ± 21 -22.7 ± -3.4 
TF40 311 ± 17 -30.4 ± -4.2 
Each value represents the mean ± S.E. of 3 experiments. 
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3.3.3. Drug release properties from LC formulations 
Figure 3-2a-d show the release profile of PABA, M-PABA, E-PABA and Na-FL, 
respectively, from their LC formulations. All profiles obeyed the Higuchi’s law [29]: high 
correlation coefficients (r > 0.99) were obtained for each formulation, indicating that in vitro 
drug release profiles of drug were well fitted with the square root Higuchi model. 
For oral formulations, the amounts of PABA released from OP10D, OP10, OP20 and 
OP30 were 13.9 ± 2.5%, 23.7 ± 3.2%, 16.7 ± 2.8% and 9.6 ± 0.8% (Fig. 3-2a), respectively, 
against the initial dosing. Those of M-PABA from OM10D, OM10, OM20, and OM30 were 
6.4 ± 0.4%, 5.7 ± 0.3%, 4.2 ± 0.2% and 3.4 ± 0.4% (Fig. 3-2b), respectively, and those of E-
PABA from OM10D, OM10, OM20 and OM30 were 3.8 ± 0.3%, 3.4 ± 0.3%, 2.5 ± 0.2%, 
and 2.2 ± 0.2% (Fig. 3-2c), respectively. For topical formulations, the amounts of Na-FL 
released from TF10, TF20, TF30 and TF40 were 18 ± 0.6%, 15.5 ± 0.7%, 11.5 ± 0.6% and 
6.0 ± 0.7% (Fig. 3-2d), respectively. 
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Fig. 3-2. Effect of LC forming lipid concentration and physicochemical properties of 
entrapped drug on the release profile of PABA (a), M-PABA (b), E-PABA (c) and Na-FL 
(d) from their LC formulations. Symbols: (a): (○˖˖˖), OP10D formulation; (○˖˗˖), OP10 
formulation; (○---), OP20 formulation; (●---), OP30 formulation; (b): (□˖˖˖), OM10D 
formulation; (□˖˗˖), OM10 formulation; (□---), OM20 formulation; (■---), OM30 
formulation; (c): (˖˖˖), OE10D formulation; (˖˗˖), OE10 formulation; (---), OE20 
formulation; (▲---), OE30 formulation; (d): ( ˖˗˖), TF10 formulation; ( ---), TF20 
formulation; ( ---), TF30 formulation; ( ˖˖˖), TF40 formulation. Each point represents the 
mean ± S.E. of three experiments. 
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Although the release profile was influenced by changes in the MGE concentration, it 
was influenced more dramatically by changes in the physicochemical properties of the 
entrapped drugs. For example, the release amount of Na-FL from TF10 was 18 ± 0.6% (Fig. 
3-2d) as compared with the release of E-PABA from OE10, 3.8 ± 0.3% (Fig. 3-2c), although 
both formulations contained the same concentration of MGE. 
 
3.3.4. SAXS chart of LC formulations  
 
The phase structure of LC formulations was evaluated by SAXS. Figure 3-3a-c shows 
the X-ray diffraction profiles of OP10 (Fig. 3-3a), OP20 (Fig. 3-3b) and OM10 (Fig. 3-3c) 
formulations. Typical peaks reflection distance ratios at nearly 1, √3 and √4, revealed the 
presence of an H2 inverted hexagonal phase. The same peaks reflection distance ratios were 
observed for OM20, OE10, OE20, TF10, TF20, TF30 and TF40 (data not shown). The phase 
behavior of these formulations was determined based on international tables for 
crystallography [30, 31]. Unidentified peaks were observed for oral dry powder LC 
formulations OP10D (Fig. 3-3d), OM10D (Fig. 3-3e) and OE10D (Fig. 3-3f). 
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Fig. 3-3. SAXS charts of LC formulations: (a), OP10 formulation; (b), OP20 formulation; 
(c), OM10 formulation; (d), OP10D formulation; (e), OM10D formulation and (f), OE10D 
formulation. The peaks reflection distance ratios at: 1, √3, √4 confirm the presence of H2 
inverted hexagonal phase (a-c). The same peaks reflection distance ratios were observed for 
OM20, OE10, OE20, TF10, TF20, TF30 and TF40 (data were not shown). Unidentified peaks 
were observed for dry powder LC formulations (d-f). 
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3.3.5. Bioavailability of PABA  
Figure 3-4 shows the time course of the plasma concentration of PABA after oral 
administration of its solution or PABA-, M-PABA-, and E-PABA-LC formulations in male 
Wistar rats. Table 3-4 summarizes the calculated AUC0-6 h, Tmax, Cmax, and absolute 
bioavailability (F) of PABA after oral administration.  
The bioavailability after oral administration of OP20 (55 ± 13) (Fig. 3-5a), OM10 
(44 ± 9) (Fig. 3-5b), and OE10 (43 ± 6) (Fig. 3-5c) was significantly higher than that of 
PABA solution (16 ± 2). No improvement was observed in the bioavailability for other LC 
formulations. The Tmax of OP20 was faster compared with OM10 and OE10. The Tmax of 
OE10 was delayed to 120 min. Only OP20, OM10, and OE10 showed significant 
improvement in the bioavailability of PABA. M-PABA, and E-PABA prodrugs after oral 
administration. 
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Fig. 3-4.  Plasma profiles after oral administration of: (a), PABA-LC formulations; (b), M-
PABA-LC formulations and (c), E-PABA-LC formulations. M-PABA and E-PABA were 
metabolized to PABA after oral administration. Symbols: (a): (○˖˖˖), OP10D formulation; 
(○˖˗˖), OP10 formulation; (○---), OP20 formulation; (● ), PABA solution; (b): (□˖˖˖), 
OM10D formulation; (□˖˗˖), OM10 formulation; (□---), OM20 formulation; (c): (˖˖˖), 
OE10D formulation; (˖˗˖), OE10 formulation; (---), OE20 formulation. Each point 
represents the mean ± S.E. of three experiments. 
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Table 3-4 Bioavailability of PABA after oral administration. 
 AUC 0-6 h Tmax 
(min) 
Cmax 
(µM) 
MRT 
(min) 
F 0-6 h 
(%) 
PABA solution 876 ± 109 27 ± 6 7.4 ± 0.9 11 ± 1.8 16 ± 2 
OP10 1595 ± 440 37 ± 6 10 ± 2.7 12.7 ± 2 30 ± 8 
OP20 2939 ± 700* 46 ± 11 16 ± 3 15 ± 2.5 55 ± 13* 
OP10D 1047 ± 260 33 ± 6 8 ± 2 11.4 ± 1 19 ± 4 
OM10 2366 ± 496* 53 ± 11 12 ± 2.5 14 ± 2.1 44 ± 9* 
OM20 1167 ± 261 33 ± 6 6 ± 2 11.8 ± 2 21 ± 5 
OM10D 1072 ± 295 33 ± 6 8.8 ± 2.6 11.5 ± 2 20 ± 5 
OE10 2314 ± 348* 120 ± 21 10 ± 1.5 13 ± 2.5 43 ± 6* 
OE20 1519 ± 516 53 ± 11 6.5 ± 1.8 12.3 ± 3 28 ± 9 
OE10D 1208 ± 348 23 ± 6 7.8 ± 2 12.1 ± 1 26 ± 6 
 
Each value shows the mean ± S.E. of 3 experiments. 
AUC: Area under the plasma concentration-time curve. 
Tmax: Time to reach the maximum plasma concentration. 
Cmax: Maximum plasma concentration. 
MRT: Mean residence time. 
F: Absolute bioavailability (AUCpo/AUCiv). 
*: Significantly different from PABA solution P < 0.05 (Student’s t-test). 
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3.3.6. In vitro skin permeation profiles 
Figure 3-5 shows the effect of LC formulations on the time course of the cumulative 
amount of Na-FL that permeated through hairless rat intact skin. Significant improvements 
in skin permeation of Na-FL were observed after application of TF20 and TF30 compared 
with that from the Na-FL solution. The enhancement ratios in the skin permeation for TF10, 
TF20, and TF30 formulations were 1.7, 4.3 and 2.9, respectively, but no improvement in skin 
permeation of the Na-FL was observed with TF40 formulation. 
 
Fig. 3-5. Effect of LC forming lipid concentration on the time course of the cumulative 
amount of Na-FL. Symbols: ( ---), TF10 formulation; ( ˖˗˖), TF20 formulation; ( ---), 
TF30 formulation; ( ˖˖˖), TF40 formulation; ( ), Na-FL solution. Each point represents 
the mean ± S.E. of three experiments.  
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3.4. Discussion 
Although LC formulations have received considerable attention because of their 
excellent potential as drug delivery systems [8], there seems to be a general lack of 
understanding among researchers regarding the effect of several factors such as 
physicochemical properties of the entrapped drugs, concentration of LC-forming lipids and 
LC phase structure on the oral and topical performance of these formulations. Therefore, the 
present study mainly focused on the developing strategies of oral and topical LC formulations 
by investigating the effect of such factors to improve the performance of these formulations.  
MGE was selected as an LC forming lipid because of its low viscosity, stability and 
better drug absorption enhancer compared with other LC forming lipids [61]. I initially 
screened various oral and topical LC formulations (Table 3-2). The obtained results on their 
homogeneity and visible appearance (Fig. 3-1) showed that it was not recommended to 
prepare oral LC dispersions with MGE at a concentration of more than 30%, because these 
formulations tended to be too viscous and inconvenient for oral administration. When the 
concentration of MGE was above 40%, LC was aggregated with phase separation, therefore, 
they were inconvenient for both oral and topical formulations. In addition, MGE was not 
recommended to prepare LC dry powder at a concentration of 20% or above.  
Zeta potential is an important parameter for the evaluation of stability and bio-
distribution [40, 80]. By increasing the MGE concentration, the particle size tended to be 
smaller and the zeta potential became more negative (Table 3-3), suggesting that the number 
of LC forming particles was increased with an increase in the MGE concentration. The 
negative zeta potential of LC formulations was due to the present of free oleic acid in the 
lipid phase. The negative charge can also be explained by preferential adsorption of hydroxyl 
ions at the lipid-water interface. 
As demonstrated in Fig. 3-2, the drug release profiles from LC formulations were 
influenced by the concentration of MGE and the physicochemical properties of the entrapped 
drugs. These results indicated that the drug diffusivity in the formulation decreased with an 
increase in MGE concentration. The drug diffusivity was affected more dramatically by 
changes in the physicochemical properties of entrapped drugs. The released amount of Na-
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FL from TF10 was 18 ± 0.6% compared with the release of E-PABA from OE10 (3.8 ± 0.3%), 
although both formulations contained the same concentration of MGE (Fig. 3-2a-d). A 
similar phenomenon was observed with other drugs (PABA and M-PABA), and drug release 
decreased with an increase in lipophilicity. Figure 3-6 schematically explains the effect of 
lipid concentration and the physicochemical properties of entrapped drugs on drug release. 
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Fig. 3-6.  Illustrations explaining the effect of LC concentration (a) and the physicochemical 
properties of entrapped drug (b) on the drug release amount. The release amount of drug is 
increased by a decrease of LC concentration (a). The release amount of drug is more 
dramatically increased by a decrease of the drug lipophilicity (b).  
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Typical reflection patterns at nearly 1, √3, and √4 for oral dispersions and topical LC 
formulations indicated that these formulations successfully managed to form an H2 inverted 
hexagonal phase (Fig. 3-3a-e). Previous studies [68, 69] have reported that the hexagonal 
phase has several advantages. It has a larger surface area to interact with biological 
membranes with high fluidity, and greater amounts of drugs can be incorporated independent 
of their solubility. In contrast to our findings, other studies have demonstrated the presence 
of cubosomes using different types of LC-forming lipids such as GMO or PHT [28, 68]. I 
strongly believed that several factors might affect the phase structure of LC formulations, 
such as temperature, type of LC-forming lipid, physicochemical properties of the entrapped 
drugs, lipid concentration and type of surfactant. Further studies are necessary to fully 
understand the effect of such factors on the phase transition of LC formulations. The key 
point is to successfully prepare hexosomes or cubosomes by designing with LC formulations. 
No clear mechanism or clear evidence has been proposed to indicate that cubosomes have 
more potential than hexosomes, or vice versa, as a drug delivery system. On the other hand, 
unidentified peaks were observed in the SAXS measurement of oral dry powder formulations 
(Fig. 3-3e-f).  
The drug absorption from oral LC formulations was dramatically affected by the 
MGE concentration and the physicochemical properties of entrapped drugs (Fig. 3-4). The 
bioavailability of PABA was significantly improved by the 20% MGE formulation (OP20) 
compared with other LC formulations or PABA solution alone (Fig. 3-4a). These results 
indicated that the rate limiting step in the absorption of hydrophilic drugs must be the 
permeating process through the intestinal membrane. Thus, the hexosome particles in contact 
with the small intestine were high in this formulation (OP20) by increasing the MGE 
concentration.  
In contrast, in case of M-PABA and E-PABA entrapping formulations, a low 
concentration of MGE (OM10 and OE10) significantly improved the bioavailability of 
PABA compared with other LC formulations or PABA solution alone (Fig. 3-4b and c). 
These results indicated that the rate limiting step in the absorption process of lipophilic drugs 
with LC formulations must be their release rate. Thus, the release amount of these drugs 
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increased from these formulation (OM10 and OE10) by decreasing the MGE concentration. 
This could be also the reason why the absorption of M-PABA and E-PABA from the LC 
formulations was delayed compared with PABA-LC formulation (Table 3-4). Furthermore, 
M-PABA and E-PABA were metabolized to PABA after oral administration of their LC 
formulations, indicating that LC systems were unable to protect these drugs from intestinal 
esterase metabolite activity 
Dry powdered oral LC formulations did not manage to form hexosomes or 
cubosomes, which could be a reason why these formulations were unable to improve the 
bioavailability of PABA.  
In consequence, as the same as in the in vivo oral absorption, in vitro skin permeation 
results were dramatically affected by the MGE concentration. Significant improvement in 
the skin penetration of Na-FL was observed in 20% and 30% MGE (TF20 and TF30) with 
enhancement ratios of 4.3 and 2.9, respectively. However, no marked improvement was 
observed in 10% and 40% MGE, suggesting that a low concentration of MGE such as 10% 
(TF10) could lead to a reduction in hexosomes particles. Thus, it is necessary to overcome 
the barrier function of stratum corneum. On the other hand, a high concentration of MGE 
such as 40% (TF40) reduced drug release from the formulation (Fig. 3-5).  
The detailed mechanism of the enhanced oral drug absorption and transdermal drug 
penetration by LC systems is not fully understood yet [73, 77]. Further studies must be 
conducted to clarify the absorption-enhancing mechanism of LC formulations. 
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3.5. Chapter conclusion  
The present data showed that LC formulations are promising to improve oral 
absorption and transdermal penetration of drugs. Our findings showed that the concentrations 
of LC-forming lipid and the physicochemical properties of entrapped drugs are very 
important factors that should be considered by researchers in this field to improve the 
performance of LC formulations in various pharmaceutical applications. Understanding the 
effect of these factors on the LC formulation performance could enable researchers to 
develop LC formulation approaches that intended to improve the oral absorption and skin 
permeation of drugs. 
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Conclusion 
From all results obtained above, the following conclusion can be obtained: 
1. Skin drug delivering using orally dispersed LC formulations could be a promising 
achievement in cosmeceutical, dietary and clinical fields. The drug plasma concentration can 
be modified based on the type and of LC forming lipid used in the formulation design. 
2. The present results strongly suggested that the low viscosity of LC-formulations might 
influence drug diffusivity and permeability through skin. The present MGE-LC forming lipid 
can be utilized as a promising new topical formulation for therapeutic drugs and cosmetic 
ingredients. The recently developed MGE-LC-forming lipid can be utilized as a promising 
new topical formulation for therapeutic drugs and cosmetic ingredients. 
3. The concentrations of LC-forming lipid and the physicochemical properties of entrapped 
drugs are very important factors that should be considered by researchers in this field to 
improve the performance of LC formulations in various pharmaceutical applications. 
Understanding the effect of these factors on the LC formulation performance could enable 
researchers to develop LC formulation approaches that intended to improve the oral 
absorption and skin permeation of drugs. 
The findings of this study showed that LC formulations, such as cubosomes and 
hexosomes, represent an important class of biocompatible amphiphiles and their application 
can be extended to several fields, such as cosmeceutical, dietary and pharmaceutical 
technologies because of their remarkable structural complexity and usefulness in various 
pharmaceutical applications.  
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